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ABSTRACT OF DISSERTATION 
 
 
 
 
THE DEVELOPMENT OF MICROFLUIDIC DEVICES FOR THE PRODUCTION OF 
SAFE AND EFFECTIVE NON-VIRAL GENE DELIVERY VECTORS 
 
Including inherited genetic diseases, like lipoprotein lipase deficiency, and 
acquired diseases, such as cancer and HIV, gene therapy has the potential to treat or cure 
afflicted people by driving an affected cell to produce a therapeutic protein. Using 
primarily viral vectors, gene therapies are involved in a number of ongoing clinical trials 
and have already been approved by multiple international regulatory drug administrations 
for several diseases. However, viral vectors suffer from serious disadvantages including 
poor transduction of many cell types, immunogenicity, direct tissue toxicity and lack of 
targetability. Non-viral polymeric gene delivery vectors (polyplexes) provide an 
alternative solution but are limited by poor transfection efficiency and cytotoxicity. 
Microfluidic (MF) nano-precipitation is an emerging field in which researchers seek to 
tune the physicochemical properties of nanoparticles by controlling the flow regime 
during synthesis. Using this approach, several groups have demonstrated the successful 
production of enhanced polymeric gene delivery vectors. It has been shown that 
polyplexes created in the diffusive flow environment have a higher transfection 
efficiency and lower cytotoxicity. Other groups have demonstrated that charge-stabilizing 
polyplexes by sequentially adding polymers of alternating charges improves transfection 
efficiency and serum stability, also addressing major challenges to the clinical 
implementation of non-viral gene delivery vectors.  
 
To advance non-viral gene delivery towards clinical relevance, we have 
developed a microfluidic platform (MS) that produces conventional polyplexes with 
increased transfection efficiency and decreased toxicity and then extended this platform 
for the production of ternary polyplexes. This work involves first designing microfluidic 
devices using computational fluid dynamics (CFD), fabricating the devices, and 
validating the devices using fluorescence flow characterization and absorbance 
measurements of the resulting products. With an integrated separation mechanism, excess 
polyethylenimine (PEI) is removed from the outer regions of the stream leaving purified 
polyplexes that can go on to be used directly in transfections or be charge stabilized by 
addition of polyanions such as polyglutamic acid (PGA) for the creation of ternary 
polyplexes. Following the design portion of the research, the device was used to produce 
binary particle characterization was carried out and particle sizes, polydispersity and zeta 
potential of both conventional and MS polyplexes was compared. MS-produced 
polyplexes exhibited up to a 75% reduction in particle size compared to BM-produced 
polyplexes, while exhibiting little difference in zeta potential and polydispersity. A 
variety of standard biological assays were carried out to test the effects of the vectors on a 
variety of cell lines – and in this case the MS polyplexes proved to be both less toxic and 
have higher transfection efficiency in most cell lines. HeLa cells demonstrated the 
highest increase in transgene expression with a 150-fold increase when comparing to 
conventional bulk mixed polyplexes at the optimum formulation. A similar set of 
experiments were carried out with ternary polyplexes produced by the separation device. 
In this case it was shown that there were statistically significant increases in transfection 
efficiency for the MS-produced ternary polyplexes compared to BM-produced poyplexes, 
with a 23-fold increase in transfection activity at the optimum PEI/DNA ratio in MDA-
MB-231 cells. These MS-produced ternary polyplexes exhibited higher cell viability in 
many instances, a result that may be explained but the reduction in both free polymer and 
ghost particles.  
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Chapter 1: Introduction 
In the early years of gene therapy, recombinant viruses were most often used as 
gene delivery vectors, but after a number of setbacks associated with immunogenicity, 
new delivery techniques have been explored. In 1995, Boussif et al. showed that the 
commercially available polymer, polyethylenimine (PEI), demonstrates gene delivery 
activity when complexed with DNA [1]. PEI and similar polymers exhibit weak or no 
immunogenicity, making them safer gene delivery vectors. Due to the comparatively low 
delivery efficiency, high cytotoxicity and aggregation in the presence of serum, however, 
conventional polymer vectors are not typically clinically viable. Many different polymers 
have been produced specifically for the purpose of gene delivery [2–8], but none have 
made polymer-based gene delivery a viable treatment option.  
 A recent method developed by a number of groups to improve polymer-based 
gene delivery is to use ternary polyplexes comprising DNA and two different types of 
polymers [2,9–13]. With this technique, polycation/DNA polyplexes are formed by 
mixing of the constituents, as in conventional polymer based gene delivery, but 
subsequently the polyplexes are exposed to a second anionic polymer. The anionic 
polymer forms a complex with the cationic binary polyplex, resulting in a ternary 
polyanion/polycation/DNA polyplex. For example, Wang et al. demonstrated that 
multiple ternary polyplexes exhibited increased gene delivery efficiency and reduced 
cytotoxicity in comparison to binary PEI/DNA complexes [14]. Two of the polyanions 
used were polyglutamic acid (PGA) and polyaspartic acid (PASP). It was shown that the 
ternary polyplexes aggregated much less in solutions containing serum than did the 
binary complexes, and that this enhanced the delivery efficiency of the vectors. The 
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ability to deliver genes in serum is very attractive as it more accurately models in vivo 
conditions. A problem with this approach, as with conventional polycation/DNA 
complexes, is that the assembly process is poorly controlled leading to relatively large 
particles with broad size distributions. We propose that better control of the complex 
assembly will provide more reproducible, smaller, more uniform and more efficient 
polyplexes.  
 Polymeric vectors are most commonly produced through bulk mixing of the 
components in which a polymer solution is added to a solution of plasmid DNA followed 
by mechanical mixing (i.e., shaking or vortexing). This method most often produces 
particles between 200-500 nm in diameter [15]. Sizes can be controlled to some extent by 
varying the polymer:DNA ratio, but the resulting size distributions are heterogeneous. 
Several recent publications have reported the assembly of gene delivery vectors in 
microfluidic (MF) devices [16–18].  Koh et al. demonstrated a MF device that was 
capable of producing smaller and more uniform PEI/DNA complexes [16]. This device 
passes a plasmid DNA (pDNA) stream through a central channel that is flanked on either 
side by streams of PEI. Due to the laminar flow environment, characteristic of MF 
channels, the polymer can reach the DNA by diffusion only. This controlled environment 
is ideal for the assembly of small monodisperse particles. It was demonstrated that 
polyplexes produced this way exhibit higher gene delivery efficiency than those produced 
by bulk mixing [16]. Neither their MF system nor, to our knowledge, any yet reported 
provides for layer-by-layer assembly of ternary polyplexes, however.  
 Polymer-based gene delivery demonstrates great potential for the treatment of a 
variety of diseases. Since this method does not involve viral components, it bypasses the 
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negative immune responses associated with viral gene delivery. Through a 
multidisciplinary approach combining microfluidics and drug design, the proposed 
research project seeks to address major barriers hindering polymer-based gene delivery 
from entering the clinic. We suggest that the controlled mixing environment provided by 
the MF device combined with the functionality of ternary polyplexes will result in layer-
by-layer (LbL) assembly of particles capable of increased delivery efficiency, reduced 
cytotoxicity and functionality approaching that of a virus.  
 
1.1 Specific Objectives 
The primary objective of this work was to design microfluidic devices for the removal of 
free PEI and the production of ternary polyplexes. The specific objectives of the three 
experimental chapters are shown below. 
 
1.1.1 Literature Review of Ternary Polyplexes  
 In order to fulfill the primary objective of this work, a thorough literature review 
of ternary polyplex examples is necessary. Here I show how ternary polyplexes fit in to 
the gene delivery environment and give specific mechanisms by which the addition of 
anionic polymers aid in gene delivery. I then describe key categories of polymers that 
have been explored, examine which cellular barriers to delivery the polyplexes were 
designed to overcome, and highlight points in which research could be expanded. The 
goal of this review is to give insight into TP design and formulation for further 
application in microfluidics. 
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1.1.2 Literature Review of Microfluidic Device for the Production of Polyplexes 
 Similarly, a thorough literature review of microfluidic devices designed to 
produce polyplexes was carried out to aid in the realization of the primary objective. In 
this section I provide a brief review of the broader context in which microfluidics fits and 
then discuss devices that have been designed specifically for the production of 
polyplexes. Two categories of devices are defined, specific examples of the results from 
experiments carried out in devices from both categories are explored, and areas in which 
I believe research could be expanded are highlighted. The goal of this review is to gain 
understanding about specific designs and polymer systems that have been employed for 
polyplex generation. 
 
1.1.3 Design, Development, and Validation of a Microfluidic Separator Device for the 
Production of Polyplexes  
 After gaining understanding of previous MF designs that have been employed for 
the production polyplexes, computational fluid dynamic models of novel device designs 
were created. Important parameters highlighted in the literature were explored using the 
model to aid in the design of a microfluidic separator (MS) device. After determining the 
appropriate geometry of the device, I fabricated the device using photolithographic 
techniques described in more detail below. The device was then validated for flow 
performance using fluorescence flow characterization. The physicochemical properties of 
the MS-produced polyplexes were determined and compared to conventional BM-
produced polyplexes. Finally, I carried out transfections in three human cell lines and 
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compared gene expression and toxicity for bulk-mixed and MS-produced binary 
polyplexes. 
 
1.1.4 Comparing Different Mixing Methods and Molecular Weights for the Production 
of Ternary Polyplexes 
 Having designed and validated a device for the production of PEI/DNA 
polyplexes, I then explore the effects of different mixing methods, based on previous 
techniques from literature, on gene expression in human cells. A key advantage of TPs is 
their ability to maintain higher gene expression levels in media containing serum, so I 
compare transfections from the TPs in both serum-free and serum-containing media. 
Simultaneous experiments looking at the effect of PGA molecular weight on transfection 
efficiency were carried out and helped to establish an optimized molecular weight for 
transfection. This leads to the use of the material in future microfluidic formulations.  
 
1.1.5 Microfluidic Production of Ternary Polyplexes and Comparison of Different 
Production Methods 
 A sequential MF mixer was then designed for comparison with BM and MS 
methods for the production of TPs. The physicochemical properties of the TPs produced 
by each method were then compared. Transfections were then carried out to probe the 
gene expression and toxicity of TPs produced by each method on three different human 
cell lines. Additional transfections were carried out to explore the cellular uptake through 
flow cytometry experiments on the HeLa cell line. The final sample composition was 
then assessed to determine the amount of free PEI and potential for ghost particles.  
6	
	
 
1.1.6 Concluding Remarks 
 Conclusions drawn from the research are given and future directions of the 
research, as understood by the author, are given. 
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Chapter 2: Literature Review of Ternary Polyplexes 
 
2.1 Introduction 
Gene therapy is the treatment of diseases through the use of genetic material 
which codes for proteins that, when produced by a target cell, produce therapeutic effects 
by replacing a disease-causing gene, making a disease-causing gene inactive, or 
introducing a novel gene into the body to help treat a disease. Genetic diseases are 
obvious targets of for this type of therapy since the replacement of faulty genes with 
“normal” genes may cure the disease. An example of one such disease is lipoprotein 
lipase deficiency, for which a gene therapy drug has already been approved in Europe 
[19]. Other genetically inherited diseases that have been targeted by gene therapy 
researchers include hemophilia [20], severe combined immune defficiency [21], 
adrenoleukodystrophy [22], Leber congenital amaurosis [23], and others [24–26]. In 
addition to inherited genetic disorders, gene therapy has also been used to treat diseases 
that are acquired such as cancer. Cancer treatment makes up the bulk of gene therapy 
research [27], and a variety strategies have been employed such as suicide gene therapy 
[28], oncolytic viral therapy [29], antiangiogenisis [30] and immunotherapies [31]. Other 
acquired diseases for which gene therapies have been studied include neurodegenerative 
diseases such as Parkinson’s disease [32] and Huntington’s disease [33], and also 
infectious diseases like HIV [34] and hepatitis [35].   
With such broad applicability and high potential for treating or curing diseases, 
gene therapy has gained a lot of attention among health science researchers and the 
general media. Generally, there are two primary methods of delivering genetic material: 
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viral vectors or synthetic vectors. In most cases the vector used to deliver the genetic 
material is a modified virus such as adeno-associated viral (AAV) vectors [36], lentiviral 
vectors [37], and retroviral vectors [38]. While these viral vectors have had some success, 
there are safety concerns associated with their use such as oncogenisis [39], 
immunogenicity [40], limited cell specificity [41], as well as safety concerns and 
complications associated with the large-scale production of viruses [42]. 
In comparison to viral vectors, synthetic vectors offer a potentially safer 
alternative by sidestepping many of the issues highlighted above [43] [44]. These non-
viral vectors include polymers [45], cationic lipids [46], metallic nanoparticles [47], and 
hybrids of all of these. In general, these materials are weakly or non-immunogenic; often 
contain easily modifiable chemistries, which make them amenable to cell-specific 
targeting; and are easily adapted to common chemical processing. In spite of these 
advantages over their viral counterparts, synthetic vectors have had little clinical success. 
This is due to their comparatively low gene delivery efficiency, which is a result of their 
inability to overcome delivery barriers including the need for stability in serum and 
protection of their genetic cargo, cell-specific targeting, cellular internalization (often 
through endocytosis), endosomal escape, and transcription.  
Ternary polyplexes (TPs) offer a potential solution to the problems presented by 
both viral and traditional synthetic vectors. TPs comprise nucleic acids, ionic polymers, 
lipids or metallic nanoparticles, which form nano-sized complexes through entropic 
interactions that are capable of gene delivery [Fig. 2.1].  These vectors are capable of 
addressing multiple delivery barriers, while often doing so in sequence allowing for  
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Figure 2.1: Schematic of a typical ternary polyplex bulk mixing method where binary 
polycation/DNA polyplexes are formed and then coated with polyanions.   
10	
	
programmed gene delivery. In this review, we will look at a variety of TPs that have been 
explored and compare the ways in which researchers are attempting to solve the problems 
of low delivery efficiency and toxicity associated with synthetic vectors. Here we will 
identify five broad categories of ternary polyplexes and summarize some important 
examples and their findings. There will be some overlap between categories, for example 
many peptide and synthetic polymer containing TPs are targeting, but we have made 
every attempt to categorize them into the most pertinent categories. 
 
2.2 Types of Ternary Polyplexes 
 
2.2.1 Ternary Polyplexes Generated Using Conventional Gene Delivery Materials  
Off-the-shelf TPs where the constituent polymers are used without any further 
chemical modification or purification. The advantage with this type of polyplex is that it 
is simple to use and should translate easily to an industrial production environment. Due 
to these attributes, off the shelf TPs represent one of the more economically and 
industrially viable types of TP.  
For example, Kurosaki et al. investigated a variety of off the shelf polynucleic 
acid- and polyamino acid-coated PEI/DNA polyplexes for uptake, gene delivery 
efficiency and toxicity [48]. The polyanions included polyadenylic acid (polyA), 
polyinosinic-polycytidylic acid (polyIC), α-polyaspartic acid (α-PAA), α-polyglutamic 
acid (α-PGA) and γ-polyglutamic acid (γ-PGA). Of all the tested polyanions, γ-PGA 
showed the most promise, demonstrating transgene efficiencies similar to that of binary 
PEI/DNA polyplexes, while exhibiting much less toxicity than the control in B16-F10 
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cells. Though only γ-PGA was shown to be effective at delivering DNA, all polyanion-
coated polyplexes were shown to be much less toxic than the binary polyplexes. These 
results, along with dynamic light scattering and zeta potential measurements showing that 
the outside of the particle is coated and negatively charged, suggest that neutralization of 
the positively charged amine groups associated with the PEI is essential for decreasing 
the toxicity of polycation based synthetic vectors. In fact, in a follow up paper by the 
same group, γ-PGA was also shown to decrease the toxicity of a variety of cationic lipids 
and polymers [polypeptides poly-L-arginine hydrochloride (PLA) and poly-L-lysine 
hydrobromide (PLL), and the liposomes N-[1-(2, 3-dioleyloxy) propyl]-N, N, N-
trimethylammonium chloride (DOTMA)-cholesterol (Chol) and DOTMA-
dioleylphosphatidylethanolamine (DOPE)], demonstrating that anionic coatings can help 
reduce the toxicity in multiple types of cationic complexes [15]. Since γ-PGA 
demonstrated significantly greater gene expression and cellular uptake of polyplexes 
compared to the other polyanions, the authors suggest that polyplexes coated with γ-PGA 
may be internalized through a receptor-specific mechanism. Through inhibition studies 
involving hypothermia, excess γ-PGA, or the combination of both, the authors conclude 
that the γ-PGA polyplexes are taken up by an energy-dependent process and a γ-PGA 
specific receptor mediated pathway. However, additional uptake studies need to be 
carried out to identify the specific uptake pathway. 
 Wang et al. also explored some off-the-shelf polyanions to create TPs with PEI 
and DNA, and demonstrated similar results showing increased transfection efficiencies 
and decreased toxicity in HeLa cells [13]. Here the researchers used off the shelf anionic 
polysaccharides alginic acid (ALG) and heparin (HEP), as well as α-PAA of molecular 
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weight 10 kDa (α-PAA10) and α-PGA of molecular weight 7 kDa (α-PGA7). A primary 
outcome of this research is the demonstration of advantages that TPs have in serum-
containing media. The group carried out transfections in both serum-free media and 
media containing 10% fetal bovine serum (FBS) and demonstrated a maximum of ~15% 
increase in gene delivery in both conditions when compared to either PEI/DNA 
polyplexes or Lipofectamine 2000. Demonstrating increased transfection activity in 
serum-containing media is an important step towards making non-viral gene delivery 
clinically viable, since the environment mimics that of in vivo administration. Isothermal 
titration calorimetry (ITC) showed that the TPs have a decreased binding affinity with 
serum proteins, which provides an explanation for the increased transfection efficiency in 
the presence of serum. Since serum proteins are less likely to adsorb on the polyplex 
surface, the authors conclude that the vectors undergo less aggregation and are less likely 
to experience interference from the proteins during uptake. The researchers further 
demonstrated that loosening of the compact DNA/PEI polyplexes occurs with the 
introduction of polyanions, which is due to competition between the anionic phosphate 
groups associated with the DNA and cationic groups associated with the polyanion. They 
went on to show that there was a pKa-dependent critical value of Acid/Amine ratio over 
which DNA dissociates completely from the TPs. There is a discrepancy between the 
work of the two groups in that Kuorsaki et al. showed no transfection activity for α-PGA 
and α-PAA while Wang et al. showed dramatically increased transfection activities in 
either case when compared to PEI/DNA polyplexes. Additionally, there are large 
differences between the particle sizes reported in the two papers for TPs comprising 
similar constituent polymers. Either of these discrepancies could be due to differences in 
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molecular weight of the polyanions (the molecular weights of the polyanions are not 
given by Kurosaki et al.). Wang et al. investigated a range of polyanion/DNA ratios 
whereas Kurosaki et al. reported only one ratio, which may not be the optimal ratio. 
Another possible reason for the difference in transfection activities is that different cell 
lines were employed in these two studies. 
 Urtti et al. demonstrated the use of hyaluronan (HA) of a variety of molecular 
weights to coat PEI/DNA polyplexes and shield the positive charge of the polyplex 
without affecting the transfection efficiency and increasing the complex stability [49]. 
Interestingly, the HA facilitated uptake by the CD44 receptor, which is prevalent on the 
ocular surface. In this case the researchers were focused on ocular delivery as the eye 
provides the advantage of cell-specific targets, and it is an immune-privileged area. 
Transfections of human corneal epithelial (HCE) cells with HA/PEI/DNA TPs 
demonstrated increased transfection activities when the HA molecular weight was less 
than 10 kDa, in comparison to DOTAP/DOPE lipoplexes and PEI/DNA polyplexes. 
Uptake studies carried out using flow cytometry indicate that the low molecular weight 
HAs facilitate CD44 receptor-mediated uptake, though further exploration is needed to 
determine the optimum molecular weight for maximum CD44 binding affinity.  
 Human serum albumin (HSA) has also been employed as an off-the-shelf 
polyanion for the production of TPs [50]. In this case, Nicoli et al. used HSA to coat 
PEI/siRNA complexes to demonstrate knockdown of TurboGFP in MDA-MB-231 and 
human primary pulmonary microvascular endothelial cells (HPMEC) cells. These HSA-
coated TPs demonstrated enhanced gene silencing in comparison to PEI/DNA polyplexes 
and comparable transfection efficiency to that of Lipofectamine 2000. Similar to other 
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papers, the researchers demonstrated negative zeta potentials for the TPs suggesting that 
the polyplexes would have charge-shielding potential and enhanced stability in 
circulation. TP sizes were determined through DLS and shown to be similar to that of 
other TPs. TP cellular internalization was shown to be facilitated by caveolin-mediated 
endocytosis, which provides an explanation for the role of HSA in the internalization of 
the polyplexes. TPs containing bovine serum albumin in place of HSA exhibited a similar 
particle size but exhibited a significant decrease in transfection efficiency. This result 
suggests that HSA offers some specificity in the uptake of the cell lines investigated, 
though further investigation is required.   
 
2.2.2 Ternary Polyplexes Comprised of Synthetically Modified Polypeptides (SPP)  
TPs may be generated in which one or both of the polyanion and polycation are 
synthetic polypeptides. A major advantage of the use of polypeptides is that, in the 
context of the cellular barriers to delivery, they maintain the advantages of off-the-shelf 
polyanions while providing additional functions for overcoming important barriers to 
efficient gene delivery. However, polypeptides are generally more difficult and expensive 
to synthesize compared to most synthetic polymers and are likely more immunogenic 
than synthetic polymers. 
 Chen and co-workers developed polyethylenimine-poly(L-lysine)-poly(L-
glutamic acid) (PELG) and OEI-poly(benzyl-L-aspartate)-poly(benzyloxycarbonyl-L-
lysine) (OEI-PBLA-PLys(Z)) (OEAL) as zwitterionic polymers for use in TP 
formulations [51,52]. PELG and OEAL were shown to be pH responsive polymers that, 
when used in TP formulations and exposed to a mildly acidic environment, demonstrate 
15	
	
charge conversional behavior changing from negative to positive surface charge. When 
binary PEI/DNA polyplexes were coated with PELG or OEAL at physiological pH, the 
surface charge of the TPs is negative. As is the case with the TP systems mentioned 
above, this negative surface allows for less aggregation due to decreased association with 
serum proteins. However, when these zwitterionic coated TPs enter an acidic 
environment such as that of a tumor, the surface charge of the TPs rapidly changes to 
positive. For example, the zeta potential changed from ~-20 mV at pH of 7.4 to 25 mV 
and pH 6.8. Since the pH of tumors is lower than that of normal tissues, these pH 
responsive systems offer a way in which to target cancerous growths using a non-viral 
vector by activating the TP when in the proximity of tumors. Transfections at pH 7.4 and 
6.8 were carried out to mimic either the normal cellular environment or tumor 
environment, respectively. The PELG and OEAL TPs demonstrated a more than 10-fold 
increase in transfection activity at the lower pH, showing both the advantage of positive 
polyplex surface charge in transfection and that of negative polyplex surface charge in 
charge-shielding in vitro. Since a primary justification for the necessity of charge 
shielding with TPs is aggregation with serum proteins, the researchers went on to 
investigate the in vivo efficacy of the TPs. BALB/C nude mice with HeLa xenograft 
tumors were given intratumoral injections of TPs carrying a gene coding for rev-casp-3, 
which was engineered by the same group to have high apoptotic activity [53]. The tumor 
mass was monitored over a period of 20 days and both PELG and OEAL TPs 
demonstrated higher inhibition of tumor growth than the positive controls with tumors 
treated by PELG TPs having a reduction in volume of ~30% in comparison to tumors in 
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untreated mice and those treated with OEAL TPs having ~70% smaller tumor size than 
tumors in untreated mice. 
 Another example of a modified polypeptide used for gene delivery is 
carboxymethyl poly(L-histidine) (CM-PLH) [54]. Asayama et al. first reported the 
synthesis of the carboxymethyl-modified polypeptide and demonstrated the pH 
responsive capabilities of the molecule [55]. Including an imidazole containing 
polypeptide group in the TP formulation allowed for improved solubility in aqueous 
solutions at pH above 6.0 and enhanced membrane disruptive abilities at lysosomal pH. 
The addition of the carboxymethyl groups allowed for charge shielding effects similar to 
other polyanions, while the imidazole group allowed for enhanced buffering capacity 
leading to endosomal membrane disruption and escape. The researchers went on to use 
the novel anionic polypeptide to coat binary PEI/DNA polyplexes to create CM-
PLH/PEI/DNA ternary polyplexes. They went on to show that the surface charge, 
determined through zeta potential measurements, was close to neutral demonstrating the 
coating of the PEI/DNA polyplexes with CM-PLH. These ternary polyplexes exhibited a 
300-fold increase in gene expression over PEI/DNA polyplexes as demonstrated by 
transfections with the luciferase gene and subsequent luciferase assay.  
  
2.2.3 Ternary Polyplexes Based on Synthetic Polymers 
Like SPP constituents, synthetic polymers offer more complex molecular 
structures that address cellular barriers to delivery, often in a programmed sequential 
manner. In this case, the constituent polymers of the TP require significant chemical 
modification and purification steps, similar to synthetically modified polypeptides.  
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 One important type of synthetic polymer based TP involves the engineering of 
micelles imparting a range of functionality for overcoming cellular barriers to delivery 
[56–58]. For example, Li et al. developed a temperature-responsive TP micelle system 
consisting of two block co-polymer hybrid shells complexed with DNA [56]. The 
polymers synthesized for delivering genetic material in this case were polyethylene 
glycol (PEG) based polymer PEG-b-poly{N’-[N-(2-aminoethyl)-2-
aminoethyl]aspartamide} (PEG-b-PAsp(DET)) and poly(N-isopropylacrylamide)-b-
PAsp(DET) (PNIPAM-b-PAsp(DET)). These TPs are formed by first mixing the two 
copolymers together at 25 °C followed by addition of DNA at the same temperature, 
forming TPs with PNIPAM and PEG polymer segments on the surface. After the 
formation of the polyplexes the solution was heated to 37 °C, which is above the critical 
solution temperature for PNIPAM, which upon condensation forms a hydrophobic layer 
between the DNA core and PEG regions. This thermo-responsive formulation allows for 
more compact DNA complexation, while the hydrophobic region acts as barrier further 
shielding the DNA from nucleases in the extracellular environment, which enables longer 
circulation time for systemic delivery. These TPs demonstrated higher in vitro 
transfections in HeLa cells compared to binary polyplex micelles (BPM’s) consisting of 
DNA and PEG-b-PAsp(DET) and comparable transfection compared to Lipofectamine. 
Uptake studies were also carried out using flow cytometry and showed higher uptake of 
the TP vectors compared to binary polyplex micelles of PEG-b-PAsp(DET). The authors 
show that the enhancement of cellular uptake is due to enhanced protection in the 
extracellular environment, association of the TP with the cellular membrane due to the 
presence of the hydrophobic region, and enhanced endosome membrane disruption due to 
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the presence of free PNIPAM segments as evidenced by confocal microscopy studies and 
fluorescently labeled constituents. Since a primary goal of this research was to increase 
circulation time of the vectors and yield a TP capable of effective systemic delivery, in 
vivo experiments were also carried out by injection of the vectors into the tail vein of 
tumor-bearing mice. Blood circulation, tumor accumulation and antitumor activity of the 
TPs was probed, and in all instances the TPs demonstrated enhanced in vivo properties in 
comparison to BPMs. Most notably, the TPs efficiently delivered sFlt-1 pDNA to tumor-
bearing mice, eliciting strong antitumor activity. The TP micelles were administered to 
the mice for 12 days and at the end of the period the relative volume of the tumors was 
half of that of tumors from mice treated in the same manner with BPMs. 
Another interesting example of a ternary polyplex micelle system is the 
development of a photosensitive vector by Nomoto et al. [57]. In this case a triblock 
copolymer PEG-b-PAsp(DET), modified further to include poly(L-lysine) (PEG-b-
PAsp(DET)-PLys), was developed as the DNA-condensing polymer. The PLys segment 
complexes with the DNA forming a stable core compartment, the PAsp forms an 
intermediate compartment for incorporation of a photosensitizer and the PEG segment of 
the polymer forms an outer shell. Finally, the light-responsive dendrimeric 
phthalocyanine derivative (DPc) was incorporated into the intermediate PAsp 
compartment through electrostatic interactions. Keeping the DNA and DPc segregated 
into different compartments is essential to prevent inactivation of the DNA by the DPc 
through the formation of reactive oxygen species (ROS). The group demonstrated 
enhanced physicochemical properties of the TP in comparison to the BPM via TEM, 
FRET and DLS analysis. Notably, the inclusion of the DPc resulted in smaller average 
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particle sizes at a DPc/Asp(DET) ratio of 1:1. FRET analysis showed a decrease in FRET 
efficiency, defined as the ratio of fluorescein intensity to Cy3 fluorescence intensity, for 
two control samples. The control samples in this case are a randomly mixed sample of 
pDNA, DPc and PEG-PAsp(DET)-PLys and a sample without the intermediate 
compartment, which was prepared by adding DPc to a pDNA/PEG-PLys polyplex 
micelle. The results indicated that the DPc TP formed a three-layer system where DNA 
preferentially associates with the PLys layer. In vitro experiments with the DPc-based 
TPs was carried out in both HeLa and HUVEC cell lines, checking for cellular 
localization, cell viability and protein expression. Localization studies indicated that TPs 
that did not undergo photo irradiation showed little escape of the DNA from 
endolysosomes, while photoirradiated TPs demonstrated a high degree of DNA escape 
from the region. Viability studies demonstrated that TPs containing higher levels of DPc 
caused a greater degree of cytotoxicity upon irradiation, presumably due to ROS 
interactions with the cellular membrane and organelles. The DPc based TPs demonstrated 
fluence dependent protein expression with DPc/Asp(DET) ratios of one and two, 
demonstrating significant increases in expression after irradiation and performing about 
the same for either ratio. As with most cases performance in vivo after systemic 
administration is a key concern, and the group carried out in vivo studies in mice with 
subcutaneous HeLa and HCT 116 tumors by transfecting the Venus (yellow fluorescent 
protein) reporter gene. Photoirradiation was carried out with a semiconductor laser and 
photoirradiated tumors demonstrated nearly a 5-fold increase in fluorescence, proving 
photoresponsive materials can be a viable way to initiate endosomal escape at a specific 
place and time during the transfection process.  
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Finally, Lai et al. have developed a PEG-b-PAsp(DET) ternary polyplex system 
with a unique bioreducible coating polymer with cleavable disulfide linkages similar to 
polymers mentioned previously [51,58,59]. The engineered bioreducible polymer used in 
this instance is poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)-b-
PAsp(DET) (P(EPE)-b-PAsp(DET)) that was further modified to include a disulfide 
linkage yielding P(EPE)-SS-PAsp(DET). The P(EPE) segment allows further membrane 
disruption through amphiphilic association and subsequent disruption of the endosomal 
membrane in synergy with the membrane disruption properties associated with the 
PAsp(DET) segments. With a predetermined W:W value, particle characterization using 
DLS was carried out and demonstrated comparable particle sizes to other polyplexes, ~70 
nm. As expected, the increasing addition of PEG-b-PAsp(DET) resulted in increasingly 
negative zeta potentials for the polyplexes. The addition of 10 mM DTT reducing agent 
resulted in positive surface charge over time which is attributed to the cleavage of the 
disulfide linkages, showing that the TPs would be responsive in reducing environments 
such as the endosome. Stability of the P(EPE)-SS-PAsp(DET) TPs was comparable to 
other PAsp(DET)-based TPs at physiological salt concentrations, as indicated by DLS 
analysis of the TPs over a period of 60 min where particle sizes were static at below 100 
nm. In vitro transfections with the P(EPE)-SS-PAsp(DET) TPs were compared to 
P(EPE)-b-PAsp(DET) TPs of similar composition in MDA-MB-231 and A549 cell lines. 
The inclusion of the disulfide linkage resulted in as much as 2- and 9-fold higher 
transgene expression for disulfide-linked TPs when compared to those not containing the 
reducible bond, in MDA-MB-231 and A549 cell lines, respectively. Cytotoxicity 
differences between the two types of TPs was negligible and much less than PEI/DNA 
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polyplexes in both cases. It was also demonstrated that disulfide containing TPs were 
internalized much more efficiently than other TPs, though differences became marginal 
as PEG-b-PAsp(DET) percentages increased above 50%. 
 A system described by Sanjoh et al., which includes a synthetically modified PEG 
backbone like many other examples, demonstrates a dual pH-responsive behavior 
overcoming multiple cellular barriers in sequence [60]. Thiolated poly(L-lysine) was 
used as the complexing cation to form the binary polyplex core. An important distinction 
between this TP example and others is that in this instance the thiol groups in the core 
become crosslinked via pH-responsive disulfide bonds. The binary crosslinked polyplex 
is then coated with PEG-b-PAsp(DET) that has been modified with anionic cis-aconitic 
groups, PEG-b-PAsp(DET-Aco), to create a ternary cross-linked polyplex (PEG-CCP). 
As the cellular endosome begins to acidify, the PEG-CCP coating destabilizes and 
dissociates from the core, as demonstrated by monitoring zeta potentials of TPs over time 
at pH 5.5 and 7.4. It was demonstrated that the TPs exposed to the lower pH underwent a 
zeta potential change from -20 mV to 30 mV, while there was no change for TPs at the 
higher pH. The authors argue that the change in surface charge demonstrates that at 
endosomal pH the anionic cis-aconitic groups have been removed and PEG-b-
PAsp(DET) dissociates from the TP leaving the more positively charged surface. This 
dissociated PEG-b-PAsp(DET) then begins to destabilize the endosome/lysosome 
membrane, similar to other PEG based polymers mentioned above, allowing for the 
escape of the cross-linked core into the cytoplasm. To investigate the stability and 
decomplexation of the TPs, polyanion exchange experiments were carried out in both 
reducing and non-reducing environments with dextran sulfate. Both the binary cores and 
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the TPs were investigated and compared to non-crosslinked binary cores and TPs with a . 
poly[N-(N’-uccinyl-2-aminoethyl)aspartamide] PAsp(EDA-Suc), a coating that doesn’t 
have charge conversional functionality. In non-reductive conditions, the crosslinked cores 
and TPs demonstrated a significant increase in stabilization in comparison to their non-
crosslinked counterparts. The crosslinked cores and TPs also released DNA in reducing 
environments through the cleavage of the disulfide bonds in the core. Further 
experiments demonstrated enhanced transgene expression with the TPs when transfecting 
HuH-7 and HUVEC cell lines in vitro and comparing to transfections with the 
PAsp(EDA-Suc) TPs coated and polyplexes formed by only non-crosslinked cores. Cell 
viability experiments demonstrated low cytotoxicity of the TPs and the same controls, 
and importantly demonstrated that coating the binary cores with PEGylated polyanions 
significantly reduces poplyplex toxicity. Using fluorescently labeled DNA and 
LysoTracker Green stain, the researchers were able to demonstrate that less DNA was 
associated with the endosomes and lysosomes with the TPs in comparison to controls, 
which further demonstrates the ability of the TPs to efficiently escape endosomes. This 
increase in endosome escape was attributed to the charge-conversional PEG-b-
PAsp(DET-Aco) coating. 
 Another synthetic polymer engineered for overcoming cellular barriers to gene 
delivery as a TP component has been introduced by Wang et al. [14]. This TP also 
exhibits targeting, charge conversion, membrane disruption and self-dissociation 
functions. In this case the DNA core consists of the common PEI/DNA polyplex, and 
lauric acid-polyethylenimine-cyclohexanedicarboxylic anhydride-folic acid (LPHF) was 
synthesized as a charge conversional coating. Endosome escape in this case is mediated 
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by the proton sponge effect, as with other PEI-containing polyplexes. LPHF coated TPs 
demonstrated a larger particle size of ~300 nm at LPHF/PEI weight ratios 0 – 2, but upon 
further addition of LPHF the particle sized decreased to ~100 µm, similar to the size of 
PEI/DNA particles. Zeta potential measurements mirror those of off-the-shelf TPs, 
starting at ~25 mV for PEI/DNA and becoming increasingly negative with the addition of 
the LPHF, achieving a minimum surface charge of ~-35 mV. Since the TPs were 
expected to dissociate and release the PEI/DNA core in acidic conditions, particle size 
and zeta potential at different pH was investigated. Particle sizes and zeta potentials of 
the TPs were shown to be constant over a period of 12 hours at physiological pH. Over 
that same period at pH 6 or 5, both particle size and zeta potential increased, indicating 
pH-dependent dissociation of the LPHF from the PEI/DNA core. The LPHF polymer 
exhibited little cytotoxicity, with HeLa and A549 cell lines exhibiting similar viabilities 
to untreated controls both in media containing serum and serum-free media. Additionally, 
TPs exhibited less toxicity than PEI/DNA polyplexes, further demonstrating the 
ameliorating effect of charge shielding on cellular toxicity. Flow cytometry experiments 
probing cellular uptake of the LPHF TPs were carried out by transfecting folate positive 
HeLa and folate negative A549 cell lines, and additionally adding excess folate in some 
circumstances to probe inhibition. It was shown that transfections of the HeLa cell lines 
yielded a two-fold increase in fluorescence over the A549 cells when transfected with the 
TPs while the same cell lines transfected with PEI/DNA polyplexes yielded about the 
same fluorescence signal. Similarly, the folate inhibition assay showed ~ 45% reduction 
in fluorescence signal when excess folate was present in HeLa cells transfected by the 
TPs, both experiments providing strong evidence indicating folate-mediated endocytosis. 
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EGFP reporter gene transfections further indicated that LPHF TPs were more efficient 
gene delivery vectors than PEI/DNA polyplexes, exhibiting nearly a 3-fold increase in 
transfection efficiency in both HeLa and A549 cell lines. Another interesting finding is 
that while PEI/DNA polyplexes showed higher cellular uptake in comparison to LPHF 
TPs, the LPHF TPs demonstrated higher gene expression. This result demonstrates the 
importance of the dissociation of the coating polymer from the binary polyplex core. 
Cellular trafficking studies, carried out by labeling the PEI with FITC, staining the cells 
with Lysotracker and observing them at different time points, revealed that PEI/DNA 
polyplexes remained trapped in the endosome much longer than the LPHF TPs providing 
further validation of the inclusion of multiple functional entities to overcome cellular 
barriers to delivery. In vivo studies were also performed using nude mice with HeLa 
tumor xenografts and near-infrared fluorescence imaging at the tumor site. Results 
suggested that systemic delivery of the polymers was effective at both targeting tumors 
and decreasing tumor size. LPHF TPs also showed less noticeable effects on the body 
weight of the mice suggesting less drug associated toxicity on the mice. 
 
2.2.4 Ternary Polyplexes Involving Metallic Nanoparticles (NPs) 
TPs have been constructed using metallic NPs that are, in most cases, coated to 
allow polyelectrolyte complexation with the surface of the particle. Since metallic NPs 
generally are very monodisperse with well-defined geometries, they can be used as 
scaffolding onto which encourage enhanced TP size and uniformity and, in many 
instances, metallic NP based TPs allow for functions beyond gene delivery. 
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Elbakry et al. demonstrated the use of gold NPs (AuNPs) in TP formulations [61]. 
AuNPs were chosen for their high biocompatibility, easy synthesis, simple surface 
modification, narrow size distribution and availability in a variety of sizes. To form the 
TPs, AuNPs coated in 11-mercaptoundecanoic acid (MUA) were added to a PEI solution 
where the PEI coated the AuNP due to electrostatic interactions with the MUA coating. 
The PEI-coated AuNPs were then added to an siRNA solution, and the NPs were placed 
back in a PEI solution to form a PEI outer shell yielding PEI/siRNA/PEI-AuNPs. Surface 
charge reversal between each step, as evidence by zeta potential measurements, indicated 
that the TP synthesis progressed as expected. DLS measurements further demonstrated 
that the addition of the PEI and siRNA layers led to an increase in NP size from ~18 to 
~27 nm, which is still much smaller than TPs described previously. Additional DLS 
experiments were carried out to probe aggregation of the PEI/siRNA/PEI-AuNPs in 
serum-containing media. While the TPs did aggregate, the size increased by only ~2.5-
fold, and the final TP size is still much smaller than traditional polyplexes. Interestingly, 
the zeta potential of the TPs was found to be negative after incubation with serum 
containing media. This result, along with UV-vis analysis of the TPs post serum 
incubation, indicated that serum proteins coated the surface of the TPs and helped prevent 
aggregation. While more siRNA/PEI-AuNPs, lacking the outer PEI shell, were taken up 
by CHO-K1 cells, these polyplexes tended to undergo significant aggregation within 
endosomes. In contrast, the PEI/siRNA/PEI-AuNPs showed minimal intracellular 
aggregation, which may be due to the surface interactions of the TP with negatively 
charged serum proteins. Knockdown studies carried out in a CHO-K1 cell line stably 
expressing EGFP demonstrated concentration-dependent gene silencing with a 28% 
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reduction in EGFP production at the highest initial AuNP concentration of 0.37 nM. 
However, when the PEI/siRNA/PEI-AuNP polyplexes were compared to the traditional 
PEI/DNA polyplexes, the former required a higher concentration of both PEI and siRNA 
to achieve similar knockdown. The authors hypothesized that stronger binding 
interactions and the lack of free PEI in the PEI/siRNA/PEI-AuNPs formulation resulted 
in the decreased knockdown efficiency.  
 Although not strictly a TP since it involves the use of more than three 
constituents, Guo et al. built upon the previously mentioned AuNP work by including cis-
aconitic anhydride-functionalized poly(allylamine) (PAH-Cit) in the layer-by-layer 
process to form polyplexes with charge conversional properties [62] similar to others 
previously mentioned. In this case, the PAH-Cit acts as pH-sensitive charge conversional 
moiety allowing for the release of genetic material, and overcoming strong binding 
interactions associated with PEI/AuNPs. The charge reversal process was confirmed by 
gel electrophoresis to determine the amount of siRNA that is released from the 
polyplexes at pH 5. Both DNA transfection efficiency and siRNA knockdown efficiency 
were measured in vitro with HeLa cells at a variety of Au/DNA w/w’s. In the case of 
DNA transfection, luciferase expression was shown to have a more than 3-fold increase 
in transfection efficiency at the optimum w/w of 7.5 compared to both PEI and 
Lipofectamine at an N/P of 10. In comparison, siRNA knockdown was shown to be most 
effective at a w/w of 10 by demonstration of inhibition lamin A/C expression using 
western blot techniques. Additional transfections were carried out with cy5-
siRNA/PEI/PAH-Cit/PEI/MUA-AuNPs to probe the cellular internalization and 
distribution of the polyplexes. When comparing to PEI or Lipofectamine as positive 
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controls, the fluorescently labeled polyplexes were shown to be more equally distributed 
around the cytoplasm using confocal microscopy. The positive controls, however, were 
found to be clustered together. The authors attributed the broader distribution of 
fluorescence throughout the cell, in the case of the NPs, to the siRNA being more easily 
released from the polyplex and the enhanced endosomal escape, both of which are a 
result of the charge conversional PAH-Cit. 
 Another interesting TP of this type relies on the use of superparamagnetic iron 
oxide (SPIO) NPs to allow for simultaneous gene delivery and magnetic resonance 
imaging [63].  Deferoxamine-coated Fe3O4 SPIO NPs with diameters of 8–10 nm were 
complexed with plasmids and PEI 25 kDa to create the TPs. DNA packaging of the 
polyplex system was established using agarose gel electrophoresis and the results 
demonstrated the ability of the system to effectively complex with plasmid DNA. 
Transfections were carried out on HCC HepG2 cells using the pEGP-C1 plasmid. 
Internalization was measured by colorimetric assays using the absorbance of the SPIO 
NPs and it was shown that the amount of NPs inside the cell increased with increasing 
doses of the TPs. Additionally, GFP protein production was observed visually by 
fluorescence microscopy after transfections were carried out and the uptake efficiency of 
the TPs was found to be significantly lower than that of either PEI-based polyplexes or 
Lipofectamine. The TPs were considerably less toxic than either of the positive controls 
mentioned above. Although the transfection efficiency is lower than standard transfection 
agents, the ability to include magnetic resonance imaging as a therapeutic component is 
highly attractive. Perhaps a more complex TP including a charge conversional moiety 
would increase the transfection efficiency and maintain the low toxicities. 
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2.2.5 Ternary Polyplexes Designed Specifically for Targeting 
TPs have been designed to include targeting ligands or other components that 
target specific cell surface receptors. By allowing the vectors to overcome multiple 
barriers to delivery at the same time, targeting shows great promise for aiding the 
development of clinically relevant non-viral gene delivery agents. In most cases, 
however, the specific component developed for targeting requires considerable synthesis 
effort and resources, making them potentially expensive in an industrial setting. 
 One such targeted TP, developed by Zhang et al., involves the use of folate (FA) 
to target cancer cells [64]. Many cancerous cell types over express FA receptors, while 
healthy cells exhibit limited expression, so these TPs can be used to target some tumors 
[65]. Minicircle DNA (mcDNA), a super-coiled plasmid lacking extraneous plasmid 
sequences, was employed for its advantages over conventional plasmids including 
prolonged gene expression and increased transfection efficiency. PEI was complexed 
with mcDNA to create PEI/mcDNA cores. A secondary cationic polymer, Folate-
containing PEGylated PEI (FA-PEG)m-PEI (FPP), was developed to coat the core and 
provide targeting. An interesting difference between this TP system and others mentioned 
throughout the review is that the additional FPP component contains PEI allowing for 
cellular uptake and endosomal escape, while containing the folate for targeting and PEG 
for biocompatibility. These TPs have a moderately positive surface charge, as evidenced 
by zeta potential measurements, to which the authors attribute their enhanced transfection 
efficiency in comparison to FPP/DNA binary polyplexes. The FPP/PEI/mcDNA TPs 
showed specific targeting capabilities and enhanced transgene expression levels in 
comparison to conventional polyplexes using a folic acid competition assay, with the TPs 
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exhibiting ~ 10-fold reduction in expression of luciferin at a folic acid concentration of 1 
mg/mL versus in no folic aicd treatment. In comparison at the same folic acid 
concentration there was no significant change in luciferin expression over this range of 
folic acid concentrations. TP internalization was also explored using confocal microscopy 
and FITC-labeled polyplexes. It was shown that the FPP/PEI/mcDNA TPs were 
efficiently internalized into cells and that many of the TPs were able to escape the 
endosome prior to lysosomal degradation. Further cellular trafficking studies showed that 
that the mcDNA was released from the TPs within the nucleus, showing that the TP’s 
have some ability to release the DNA. This capability may enhance gene expression and 
is attributed to the reduced electrostatic interactions between the polycation and mcDNA 
in comparison to plasmids. In vivo transfections of tumor-bearing mice further 
demonstrated the ability of the folate to target tumors overexpressing the receptor and 
enhance protein expression in comparison to conventional PEI/DNA polyplexes. While 
including folate ligands in polyplex constituents may provide an avenue for targeting 
tumor cells and the additional PEG component allows for enhanced biocompatibility, 
perhaps a polyanion modified to exhibit these properties would be more beneficial than 
PEI. As others have demonstrated, the use of anionic coatings has many benefits and in 
many cases enhances transfection– a trend that is especially pronounced in serum-
containing media. 
 A very interesting class of targeted TP that includes single strand oligonucleotides 
(ssONs) for particle surface-charge reversal and targeting was developed by Chung et al. 
[66]. The specific oligonucleotide found to assist in receptor-mediated uptake was 5’-
C10A20-3’ and was coated on histidine-conjugated polyallylamine (PAL-His)/DNA 
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polyplex cores. PAL, which contains a high concentration of amine groups, exhibits some 
of the same positive attributes as other polycations mentioned, though PAL exhibits high 
toxicity and low endosomal escape. However, when modified with imidazole-containing 
histidine, PAL is able to buffer in acidic environments. Further, similar to PEI, this 
polycation exhibits the proton sponge effect allowing for endosomal escape. The 
inclusion of the ssONs as a complexed anionic coating allows for ameliorated toxicity 
and enhanced transfection activity in serum-containing media. Particle sizes ranged from 
150 – 750 nm, with smaller particle sizes observed at higher ssONs/PAL-His ratios. Also, 
at these higher ratios the surface of the particles was negatively charged with a zeta 
potential around -30 mV. TPs formed at these higher ratios also demonstrated higher 
transfection activity than binary (PAL-His)/DNA cores and similar expression to ExGEN 
500 used as a positive control, as assessed by EGFP and luciferase expression in HeLa 
cells. HEK-293, HepG2 and Hs68 cell lines were also evaluated for amenability to 
transfection with the novel TPs via luciferase expression, and it was found that much 
higher transfection activities were noted in the HEK-293 and HepG2 cell lines in 
comparison to the Hs68 cell line, which the authors attribute to differences in the 
fibroblasts of the cells. When compared to PAL-His/DNA polyplexes, the TPs 
demonstrated a 2-, 30- and 40-fold increase in transfection activity in HEK-293, HepG2 
and Hs68 cell lines, respectively. Cellular uptake studies were also carried out in HeLa 
cells using YOYO-1 labeled plasmid along with confocal microscopy. It was shown that 
in all instances of molar ratios of ssONs/PAL-His explored, the plasmid was localized in 
the cytoplasm. To see whether dissociation ssONs occurred prior to cellular uptake, an 
additional experiment using Nulight (537)-5’-C10T20-3’ ssONs was carried out. 
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Fluorescence confocal images revealed that the YOYO-1 labeled plasmid and Nulight 
ssONs were colocalized in the HeLa cells. The researchers also compared a different 
ssONs, 5’-C10T20-3’, to the 5’-C10A20-3’ as a polyplex coating. It was found that the T-
containing ssONs demonstrated a 1000-fold decrease in transfection activity in HeLa 
cells, while having the same surface charge. These results seem to indicate that the 5’-
C10A20-3’ ssONs interacts with the cell surface to allow for polyplex delivery, but further 
experiments need to be carried out to fully understand the interaction.  
 A similar system developed by Zhang et al. involves the use of synthetic and 
natural amino acids to for the production of a family oligoaminoamides (OAA) with a 
high concentration of amine groups to allow for the proton sponge effect, and thus 
endosomal escape [67]. The synthetic amines used for construction of the OAAs are 
glutaroyl triethylene tetramine (Gtt), succinoyl pentaethylene hexamine (Sph) or 
succinoyl teraethylene pentamine (Stp), which along with natural amino acids, comprise 
low molecular weight sequence-defined polymers produced via solid phase-assisted 
synthesis. In addition to the cationic OAAs, transferrin (Tf)-conjugates were synthesized 
to target cells overexpressing the transferrin receptor (TfR), which is a characteristic of a 
number of cancers. Tf-conjugates that were explored include Tf-PLL, Tf-PEG-25PEI and 
Tf-PEG-linear PEI (lPEI). Three different mixing sequences were explored, and the 
method that resulted in the most efficient vectors was to mix the DNA and cationic 
oligomers first, followed by mixing the resulting complexes with the Tf-conjugate of 
interest. Transfection activity was greatly increased in a number of these TPs in 
comparison to previously reported polyplexes that did not contain the membrane-
disruptive OAAs. Specifically, TPs consisting of Tf-PEG-PEI, histidine-rich 4-arm 
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OAAs and DNA exhibited a 100-fold increase in expression as evidenced by luciferase 
assay in the TfR over-expressing K562 cell line. By introducing large amounts of free Tf 
during transfections, the researchers showed a 600-fold decrease in gene expression, 
suggesting that the vectors were specifically targeted to TfR on the cell surface, and that 
the vectors undergo TfR-mediated uptake. Cell viability experiments indicated that the 
vectors exhibited low toxicity. Given their targetability, high transfection activity and 
endosomal escape capability, these vectors represent a potential step towards clinical 
relevancy for TPs. However, the components to the vectors still require complex and 
involved synthesis that could be expensive on an industrial scale. 
 In an example of a more specific targeting scheme, Oliveira et al. have worked to 
develop a non-viral gene therapy to address peripheral nervous system disease [68].  
Focusing on tetanus toxin for its ability to target neuronal cells following minimally 
invasive intra-muscular injection, the group developed a TP system consisting of a 
thiolated PEI (PEISH), 5 kDa PEG-modified tetanus toxin fragment (HC) and plasmid 
DNA. The PEI was decorated with the thiol moieties to lessen intervention of the 
positively charged PEI, which is known to disrupt cell specific targeting [69]. The PEG 
was included as a spacer and to enhance complex stability in the aqueous environment 
and increase the exposure of the HC to the surface of the TP. TP size was determined to 
be 60 – 90 nm, with higher molar ratios of PEG-HC achieving smaller particle sizes. Zeta 
potential was +20–30 mV over the range of PEG-HC molar ratios explored. Binding 
specificity was investigated in ND7/23 sensorial neuron cells and NIH 3T3 cells as a 
control. As the amount of PEG-HC increased, cellular internalization decreased in NIH 
3T3 and high levels of cellular internalization in the neurons, indicating that the 
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polyplexes were capable of receptor-specific targeting. Additionally, competition by free 
HC moieties inhibited internalization of the polyplexes by the sensorial neuron cell line 
ND7/23 and including the moieties triggers specific internalization of the complexes. At 
the highest transfection and cellular internalization formulations there were signs of 
toxicity. The authors conclude that this toxicity is associated with the overexpression of 
GFP. However it seems the negative effects could be associated with free or bound PEI in 
addition to GFP overexpression since this is a known cause of cytotoxicity [70]. 
Transfections were also carried out in a dorsal root ganglion (DRG) primary cell culture, 
and both transfection efficiency and gene expression activity were assessed. Expression, 
evaluated by luciferase assay, showed significantly less gene expression for the targeted 
TPs versus conventional polyplexes, while cellular uptake was shown to be about the 
same for both vectors. However, when looking at neuron versus non-neuron cells, a 
significant increase in the proportion of transfected neuron cells was observed in 
comparison to non-neuronal cells. These results suggest that the TPs effectively target 
neuronal cells, but that some issue is present with addressing the cellular barriers to 
delivery after endocytosis. Perhaps in this case including charge conversional moieties 
would be beneficial to enhance endosomal escape and lessen the DNA/PEI binding 
interactions allowing for easier transcription of the genetic material. 
 Zhang et al. developed a targeted TP system consisting of plasmid DNA, 
Polyamidoamine (PAMAM) as the DNA condensing polycation, and polyanioninc 
heparin-modified to contain biotin ligands as the cell-targeting component [71]. Biotin 
receptors are known to be overexpressed on cancer cell surfaces, and so present an 
opportunity for targeting. The size of the TPs was about the same as PAMAM/DNA 
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polyplexes from 100 – 150 nm with slight variations when changing ratios of the 
polymers. Zeta potentials, as would be expected, are lower for the TPs in comparison to 
their binary counter parts, with the TPs showing a minimum of about 3 mV and the 
binary vectors having zeta potentials ranging from 20 to 40 mV. No significant 
differences were observed in the toxicities of the TPs and their binary counterparts. The 
biotin-containing TPs demonstrated statistically significant increases in transfection 
activities in HeLa cells over both binary PAMAM/DNA polyplexes and 
heparin/PAMAM/DNA TPs with maximum increases of 100-fold for the heparin-
biotin/PAMAM/DNA TPs over the others at a heparin-biotin/DNA weight ratio of 1 and 
optimal PAMAM/DNA weight ratio of 20. After fluorescently labeling the TPs and 
staining the cell nucleus, the cells were transfected and confocal images were taken after 
an incubation period. Comparing the images, it appears that a large number of vectors 
were located within the cells, especially around the nucleus, for the TPs in comparison to 
binary controls.  
 Gu et al. employed HA to target CD44 receptors which are overexpressed in some 
cancerous cell lines [72,73]. The TP system consists of a reducible poly(amino amide) 
(RHB) and plasmid DNA core that is coated with HA through electrostatic interactions. 
The inclusion of disulfide linkages throughout the hyper-branched polymer allows for 
degradation of the novel RHB polymer in the lysosomal environment. Particle sizes and 
zeta potentials ranged from 160 to 190 nm and -1 to -10 mV, respectively, over a range of 
w/w ratios of HA/RHB/pDNA. The TP formulations exhibited low toxicity, especially in 
formulations containing higher amounts of HA. Additionally, the HA appeared to 
ameliorate the toxic effects of the amine containing RHB polymer with binary 
35	
	
RHB/DNA vectors showing lower cell viability. Erythrocyte agglutination was assessed 
for RHB/DNA and HA/RHB/DNA polyplexes. Obvious agglutination was observed with 
the RHB/DNA vectors, and very little agglutination was seen in cells treated with higher 
amounts of HA in HA/RHB/DNA complexes. When the HA/RHB/DNA weight ratio was 
5:5:1, no agglutination was observed, which provides an explanation for the higher cell 
viability seen with this formulation since erythrocyte agglutination is associated with 
adverse effects. Cellular uptake and protein expression were assessed in CD44-positive 
B16F10 cells and CD44-negative NIH3T3 cells by transfecting with plasmid coding for 
GFP and observing fluorescence with confocal microscope or flow cytometry. Both 
protein expression and the percent of transfected cells for the B16F10 cell line was much 
higher than those of the NIH3T3 cell line. These results provide strong evidence for the 
targeting ability of the TP system. Serum resistance of the TP system was also probed by 
transfecting B16F10 with the vectors at increasing serum concentrations and carrying out 
the same flow cytometry and confocal assays. When comparing to RHB/DNA and 
Lipofectamine 2000, the TPs showed increasing enhancement of both gene expression 
and transfection efficiency with increasing serum concentration, which further 
demonstrates the ability of polyanionic coatings to improve serum stability for non-viral 
vectors. Intracellular distribution and colocalization studies were also carried out by 
tagging the DNA with YOYO-1 and lysosomes with Lyso-Tracker Red. Investigation of 
the TPs using confocal microscopy revealed that the TPs were primarily localized around 
the cell surface after two hours, and after 12 h a significant fraction was found within 
lysosomes. After 24 h, a large amount of green fluorescence was observed in and around 
the nucleus, indicating that the YOYO-1 stained DNA had escaped from degradative 
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lysosomal compartments. Inhibition studies revealed that translocation of the DNA was 
dependent on microtubules and cytoplasmic dynein, but that kinesin did not play a role in 
TP internalization.  In vivo studies to asses CD44 targeting after systemic administration 
of the TPs were carried out in C57BL/6 mice bearing pulmonary tumors. Much higher 
localization was seen in the TP formulations than that of either the RHB/DNA or naked 
plasmid. Comparing healthy Balb/c mice with tumor-bearing Balb/c mice, gene 
transfection was higher for the TPs in comparison to either naked plasmid or RHB/DNA 
polyplexes and, importantly, the lung tissue was effectively targeted as it displayed the 
highest gene expression in tumor-bearing mice. Taken together, these results suggest that 
using HA to both stabilize TP formulations for systemic administration and for targeting 
CD44-overexpressing tissues is a promising technique for advancing non-viral gene 
delivery. 
 In an effort to advance the work on HA TP systems, Liang et al. developed a 
similar system but with HA-green tea catechin complexes (HA-EGCG) as the anionic 
coating [74]. The EGCG complex is known for its ability to inhibit enzymes like 
nucleases, hyaluronidase and collagenase, which the authors intended to enhance 
systemic delivery of the TPs [75–77]. In contrast to Gu et al., the authors in this case 
employed PEI as the DNA-condensing polycation. The TPs were created by first bulk 
mixing the PEI and DNA to create the polyplex core and then mixing the HA-EGCG to 
provide the stabilizing anionic coating. Particle sizes of the HA-EGCG/PEI/DNA 
complexes were similar to that of both conventional PEI/DNA complexes and 
HA/PEI/DNA TPs. Zeta potential, as would be expected, decreased with increasing 
amounts of either HA or HA-EGCG to the TP formulations. Stabilization of the plasmid 
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by the TP was explored using agarose gel electrophoresis, and it was shown that 
HA/PEI/DNA polyplexes were unstable when treated with heparin. In comparison, the 
HA-EGCG/PEI/DNA TPs remained stable even at very high concentrations of the 
polyanion. The in vitro transfection efficiency was evaluated using CD44-positive HCT-
116 cells and CD44-negative HEK293 cells to determine the ability of the TP to target 
CD44 receptors. Greater transfection efficiency was noted for the HA-EGCG/PEI/DNA 
TPs in the HCT-116 cells in comparison to PEI/DNA polyplexes, but not in the case of 
the CD44-negative HEK 293 cells. These results, along with inhibition studies, suggest 
the ability of HA to target CD44 receptors, in agreement with previously mentioned 
results from others [49,72]. When comparing transfection efficiencies between 
HA/PEI/DNA and HA-EGCG/PEI/DNA TPs, much higher transfection efficiency was 
noted for the former as assessed via flow cytometry. The authors attribute this 
enhancement to the improved stabilization of the HA-EGCG/PEI/DNA TPs since the 
experiments were carried out in serum-containing media. In vivo experiments involving 
the systemic administration of both HA/PEI/DNA and HA-EGCG/PEI/DNA TPs to 
HCT-116 tumor-bearing mice further demonstrated the ability of the former TP 
formulation to enhance transfection for the HA-containing TP systems. These results 
further bolster the argument that the inclusion of ECGC in the system helps to stabilize 
the TP system and protect against enzymatic degradation. 
 A simpler approach to targeting was developed by Jing et al. to target metastatic 
tumors by exploiting the overexpression of metalloproteinases (MMPs) in these cells 
[78]. The system used PEI to form the TP core and then coated the particles with gelatin 
B (GPD-B), which is anionic. Since gelatin is produced by the hydrolysis of collagen, the 
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researchers reasoned that MMPs would degrade the anionic TP coating when close to 
cancerous cells, allowing for the positively charged PEI/DNA core to associate with and 
transfect the cells. C3 cells, which express a high amount of MMP, and HeLa cells, 
which express a relatively low amount of MMP, were both transfected with the TPs. It 
was shown that the GPD-B coating decreased transfection activity in the HeLa cells 
while maintaining relatively constant levels of protein expression in the C3 cell line 
compared to PEI/DNA polyplexes. This result suggests that the addition of the GPD-B 
allows for the targeting of MMP overexpressing cells by activating when they are near 
such cells. Experiments carried out to further show that the presence of MMPs degraded 
the surface coating of the TPs were undertaken. For example, by exposing the TPs to 
MMP for 6 h and comparing the zeta potentials between the treated and an untreated 
control, the researchers observed a modest increase in zeta potential as determined by 
electrophoretic light scattering (ELS). The zeta potential increase was attributed to the 
degradation of the GPD-B coating by the MMPs. Erythrocyte aggregation assays were 
carried out to demonstrate the charge shielding capacity of the TP system. When 
compared to standard PEI/DNA polyplexes the TP-treated erythrocytes demonstrated 
significantly less aggregation. Interestingly, when the TPs were first exposed to MMPs 
and then introduced to the erythrocytes, similar aggregation to that of the PEI/DNA 
polyplexes occurred. This result further suggests that the GPD-B coating is degraded in 
the presence of MMPs and releases the standard PEI/DNA polyplex core.  
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2.3 Future Directions 
Recent advances in the development of non-viral gene delivery vectors show 
great promise in advancing the vectors towards clinical relevance. With the ability to 
incorporate a variety of functions to address cellular barriers to delivery, TPs show great 
promise in leading the way to the clinic. However, there are still many obstacles that need 
to be overcome before non-viral components are the standard for gene delivery.  
 TP systems discussed in this review and elsewhere still suffer from relatively low 
gene delivery efficiency in comparison to viruses. Through stabilization of the 
polyplexes, charge conversion, degradable coatings and membrane disruption, the variety 
of polymers developed address nearly all cellular barriers to delivery, but all the 
necessary functions have not been included in a single vector since no vector to our 
knowledge includes a mechanism to address entrance into the nuclear membrane. To 
compete with viral vectors, TPs need to address the barriers in concert with minimal 
byproducts and, ideally, produced through simple and safe chemical processes. This is 
clearly a tall order, however the use of simple chemical modifications to already 
established polyplex systems may allow for the inclusion of endogenous chemical 
moieties that can address cellular barriers to delivery. These TPs could then be assembled 
in a sequential manner allowing for fully programmed delivery of genetic material, while 
maintaining biocompatibility. 
 One obstacle that is recurrent throughout the literature is the absence of standard 
practices on which to base interpretation of experimental results. For example, in many 
cases researchers seeking to advance on the work of others use different cell lines or 
modify a constituent polymer in follow up experiments. In order to more clearly 
40	
	
understand the enhancements of a particular system, transfections of the same cell lines 
would be ideal. Additionally, being consistent with the polyplex core would also be 
helpful since it would allow for a clear understanding that the modification in question is 
responsible for the observed influence.  
 In line with the above observation, standard methods for assembly of ternary 
polyplexes would also be helpful in understanding the influences of particular systems. It 
is well known throughout the field that different mixing methods can influence 
transfection results. Presumably through changing the micro mixing environment, the 
current mixing practices result in variable polyplex physicochemical properties from 
researcher to researcher and experiment-to-experiment. New developments in 
microfluidic mixing or flash nanoprecipitation may help to overcome this issue by 
providing uniform and predictable mixing environments, which lead to uniform and 
predictable products. Thus, producing TPs through one of these mixing methods may 
prove to be a useful tool for advancing the field. 
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Chapter 3: Literature Review of Microfluidics for the Production of Polyplexes 
	
3.1 Introduction 
Microfluidic (MF) devices have gained much attention for allowing researchers 
the ability to control mixing regimes and tune physicochemical properties of synthesized 
nanoparticles [79]. In addition to their applications in nanoprecipitation, MF devices have 
applicability in sensing [80], chemical analysis [81], cell sorting [82], and as components 
in many sensitive chemical instruments [83–85]. Defined by their micron and sub-micron 
scales, these devices necessarily deal with very small volumes of fluids, ranging from 
microliters down to femtoliters [86]. Geometrically confining the fluids to these small 
flow regimes results in laminar flow within the device, which means diffusion, rather 
than convection, is the dominant force controlling mixing. The common method to 
predict if a particular fluid flow is either laminar or turbulent is by calculating the 
Reynold’s number (Re) for a fluid, geometry and flow rate [Eqn. 1] [87]. 
𝑅𝑒 = 	 %&'
(
 (1) 
Where ρ is the fluid density at the relevant temperature and pressure, V is the average 
velocity of the fluid within the channel, L is the width of the channel and µ is the 
viscosity. Re less than 2000 is generally considered to characterize laminar flow, and Re 
is typically much lower than 100 and often lower than 1.0 in the case of MF devices. 
Confining the mixing to diffusion allows for the unique applications of MF 
devices whether those applications are for lab-on-a-chip chemical analysis [88], 
nanoparticle synthesis  [89], or heat exchange [90]. These microreactors also provide for 
large surface to volume ratios allowing for enhanced heat and mass transfer. Although 
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there are many interesting applications, here we will focus on nanoparticle synthesis and 
specifically on MF devices for the production of polymeric gene delivery vectors. 
By allowing for the precise control of the volumes of reactants and products, 
microreactors significantly enhance the control researchers have over chemical reactions 
leading to the formation of NPs [89]. This is desired since conventional bulk mixing 
(BM) strategies can lead to polydisperse NPs, and MF approaches can help isolate 
specific processes, such as nucleation and agglomeration that occur as NPs form in 
solution. Generally, there are two microfluidic strategies for the production of NPs, with 
much variation within each category depending on the desired product. The first utilizes 
special geometries and immiscible solvents to form droplets in which products mix, 
effectively resulting in very small batch reactors [Fig. 3.1B]. The other is continuous flow 
microfluidics, which typically leads to higher NP production rates and allows for more 
control and homogeneity of NPs [Fig. 3.1A]. 
Polymer-based gene delivery vectors are a significant type of NP with exciting 
potential to be used as clinically relevant non-viral gene delivery vectors [91]. In spite of 
their comparatively low gene delivery efficiency and potential cytotoxicity, these vectors 
typically contain chemically modifiable moieties that allow researchers to address their 
shortcomings [8,56]. Additionally, these types of polyplexes have the ability to overcome 
many of the safety and processing concerns associated with the administration and 
production of viral vectors. Chemical modification, complexation with additional 
polymers [63,92], and the use of biocompatible constituents [93] are some of the 
important techniques employed to address the many cellular barriers to delivery. Some  
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Figure 3.1: Schematics of A) a continuous hydrodynamic flow focusing microfluidic 
reactor and B) a microdroplet reactor.  
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significant strategies addressed in more detail elsewhere in the manuscript, involve the 
use of cationic polymers for their ability to condense genetic material and buffer the 
acidification of the endosome and the use of additional anionic coatings to prevent serum 
aggregation and allow for cell targeting. 
The following is a review of microfluidic strategies that have been developed for 
the production of non-viral gene delivery vectors, specifically focusing on vectors 
involving the use of polymers. Additional microfluidic strategies for generally advancing 
the field of gene therapy involve the development of devices for enhancing gene delivery 
to cells within the device. These strategies involve techniques ranging from 
electroporation [94] to the use of hydrodynamic force [95] and are outside of the scope of 
this review. For more details regarding these approaches  a complete review can be found 
elsewhere [96]. 
 
3.2 Microfluidic Approaches for the Production of Polyplexes 
 
3.2.1 Continuous Microfluidic Production of Non-Viral Gene Delivery Vectors 
Strategies in this section involve the development of devices that allow for the 
production of polyplexes on a continuous basis. These devices involve the mixing of two 
or more solutions within a device and take advantage of the laminar flow regime to create 
an interface or interfaces, depending on the specific channel geometry, through which 
genetic material and polymers mix to create polyplexes in a controlled and continuous 
manner. 
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Koh et al. created a MF system for the production of PEI/DNA polyplexes using 
hydrodynamic flow focusing to create two interfaces on either side of a DNA stream 
through which the constituent polymers could diffuse [16]. The device geometry 
consisted of a 254 x 70 µm2 cross section and 5 cm channel length in which diffusion of 
polymer into the DNA-containing stream occurs. They formed polyplexes at N/P ratios of 
3.3 and 6.7 to demonstrate that MF polyplex fabrication could result in polyethylenimine 
(PEI)/DNA polyplexes with a lesser amount of the toxic cation while maintaining or 
improving gene expression, when compared to conventional BM-produced polyplexes.  
First, the researchers explored the effectiveness of both BM and MF for condensing DNA 
by PEI. Atomic force microscopy (AFM) was used to visualize the resulting particles 
from either method, and it was observed that MF-produced polyplexes appeared to have a 
smaller size and a similar size distribution when compared to those produced by BM. 
Additional particle characterization experiments were carried out using DLS and it was 
shown that particles produced by MF were roughly half the size of those produced by 
BM with a particle size of 494 nm at the N/P ratio of 3.3. Transfection efficacy as 
assessed by GFP expression in NIH 3T3 cells was 1.2- and 1.7-fold higher for the 
polyplexes produced by MF when compared to BM polyplexes at the higher 6.7 N/P ratio 
at 2 and 4 days post-transfection respectively. Polyplexes produced by both methods 
were also tested for toxicity in NIH 3T3 cells and it was observed that MF produced 
polyplexes were slightly less toxic than conventional polyplexes as assess by MTT assay. 
The MF polyplexes showed 16% and 5% higher cell viability for the 3.3 and 6.7 N/P 
ratios respectively. Employing confocal laser microscopy (CLM) the researchers 
explored the cellular uptake and distribution by fluorescently labeling the DNA and PEI. 
46	
	
It was observed that more of the polyplexes produced by the MF device were located 
around the nucleus than those produced by BM two days post-transfection. Additionally, 
after four days fewer condensed polyplexes were observed indicating the likely 
dissociation of the DNA from the PEI by that time. 
Advancing on the previous work, Debus et al. explored a variety of microfluidic 
channel geometries and modified PEI’s for the production of polyplexes [17]. In this case 
however, Y-shaped channel designs were employed rather than hydrodynamic flow 
focusing resulting in a single diffusion interface in contrast to the two interfaces that are 
employed in previous work. Channel diffusion lengths were varied from 2 mm to 500 
mm to explore the effect of channel length on the physicochemical properties of various 
cationic polymers relevant to gene delivery. Using dyes to visualize the flow, the 
researchers observed less complete mixing in channels with shorter diffusion lengths, 
while liquids containing the dyes appeared to show some mixing in the longer channels. 
The cationic polymers that were explored were PEI, PEI 5 kDa (5PEI) and transferrin-
conjugated PEI (Tf-PEI). The researchers found that the largest impact on polyplex size 
seemed to be the ratio of polymer to DNA and that changing other parameters, such as 
the flow ratio (FR), defined throughout this thesis as the ratio of the DNA stream flow 
rate to the total flow rate, had minimal impact on polyplex size. The polydispersity index 
(PdI) of the resulting polyplexes seemed to vary with respect to flow rate in the channels 
with shorter lengths, however in the longest channel explored, 200 mm, differences in 
PdI were almost unnoticeable. PdI’s of polyplexes produced by the microfluidic device 
were generally lower than that of BM polyplexes, and fractionating PEI into low 
molecular weight fractions yielded smaller particles than other cationic polymers 
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explored. The Tf-PEI yielded the smallest particle sizes in both BM and MF preparations 
and also demonstrated significant decreases in size when micromixed. In addition to 
DNA, both siRNA and mRNA polyplexes were formed by the MF devices. Generally, 
they exhibited similar physicochemical property relationships to the DNA polyplexes, 
however there were significant differences in the physicochemical properties depending 
on which genetic material was used. 
Another type of continuous production method for polyplexes is a three-
dimensional hydrodynamic focusing (3DHF) device that was developed by Ho et al. and 
used to produce Turbofect®/DNA polyplexes [97]. In an effort to combat transverse 
diffusive broadening, a setback to 2D devices such as the ones mentioned above [98], the 
group developed a device capable of providing 3DHF yielding a laminar flow pattern of a 
center cylindrical flow sheathed around the circumference. Seeking to enhance mixing 
and thus quality of the polyplexes, the researchers developed a “hydrodynamic drifting” 
technique that is easily implementable on a planar MF device. The technique involves 
introducing a DNA stream and buffer stream side-by-side immediately before a 180º 
bend in the channel. The buffer stream is on the outer side of the bend and the centrifugal 
force induces Dean’s vortexing. Subsequently, two polymer inlets are introduced on 
either side of the DNA/buffer stream and hydrodynamically focus it producing a 
cylindrical inner DNA stream surrounded by the buffer and polymer rich sheath stream. 
Mixing is enhanced in this case since a larger surface area is produced through which 
diffusive mixing can occur. The physicochemical properties of the 3DHF-produced 
polyplexes were interrogated by DLS. A 40% reduction in average particle size was 
observed with the device versus the conventional BM method with a particle size of 262 
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nm. Polyplex size at increasing flowrates was also investigated and, in this case, it was 
found that higher flowrates lead to smaller particles over the range of flow rates and 
particle compositions tested. Particle size distribution was also shown to be much smaller 
in the case of the 3DHF device in comparison to that of BM-produced polyplexes. 
Aggregation tendencies of the polyplex produced by either method were also explored, 
and it was seen that over a period of 400 min the 3DHF polyplexes demonstrated much 
less aggregation, with no significant increase in particle sizes in the case of 3DHF and 
nearly doubling in the case of conventional BM. Transfections were carried out in HEK 
293 cells using plasmid coding for GFP for both BM and 3DHF polyplexes and 
visualized using confocal microscopy. Qualitatively, there was no difference in 
transfection efficiency, which at least demonstrates that shear stress imparted by the 
device does not negatively impact the functioning of the genetic material. Transfection 
efficiency was measured via flow cytometry, and a 15% increase in transfected cells was 
observed in the case of the 3DHF device with about ~75% of cells being transfected. 
Luciferase assays were also carried out, and a 2-fold increase in luminescence was 
observed suggesting a significant increase in gene expression for the 3DHF device. 
In a more recent example, Wilson et al. employed the same 3DHF technique for 
the production of poly(beta-aminoester) (PBAE)/DNA NPs [99]. In addition to exploring 
the physicochemical properties and common transfection endpoints of the polyplexes 
produced by the device, the group also carried out nanoparticle tracking analysis and 
looked at stability of the polyplexes after lyophylization. Particle size, as determined by 
DLS, was not observed to be statistically different between BM and 3DHF methods for 
this polycation/DNA system. The authors suggest that the difference in particle size 
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enhancement in this case may be due to PBAE being amphiphilic and of higher charge 
density than PEI, which has been the most explored polycation for MF methods. 
Transfections of GB319, B16 and MDA-MB-231 cell lines were carried out and 
transfection efficiency, gene expression and cell viability were assessed. It was shown 
that freshly produced 3DHF polyplexes performed about the same as BM particles in 
efficacy, expression and toxicity in all three cell lines. In contrast, BM polyplexes that 
were lyophilized demonstrated a significant drop in transfection efficiency, while freeze-
dried 3DHF-produced polyplexes showed little change. An additional experiment was 
carried out to assess the long-term storage potential of the freeze-dried particles, and it 
was shown that after two months of being stored at -80 °C there was no significant 
decrease in transfection efficacy. The group also developed a nanoparticle tracking 
analysis (NTA) method to assess concentration of NPs and plasmids contained per NP. 
Results for the PBAE/DNA NPs produced in this case led to estimations of about 20 
plasmids per NP. 
 
3.2.2 Droplet Microfluidics 
In this case, strategies for improving polyplex formulation methods involve the 
use of a MF device capable of creating droplets in which NP complexation to form 
polyplexes occurs. Each drop produced by the device is considered to be a microreactor 
that allows for enhanced transport of chemical species due to the short diffusion distances 
and results in more stable and uniform NP formation. In the cases discussed, there is an 
aqueous phase and oil phase, and the immiscibility forces the creation of aqueous 
droplets. 
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Grigsby et al. developed a MF droplet system for the production of polyplexes 
using either plasmid DNA or RNA and poly(amido amine) poly(CBA-ABOL) [18]. The 
cationic and bioreducible block copolymer has previously been show to possess high 
gene delivery efficiency, low toxicity, and the ability to deliver multiple types of nucleic 
acids. After establishing optimum formulations, polyplexes were formed at 
polymer/DNA and polymer/RNA ratios of 45:1 and 60:1 (w:w), respectively. Comparing 
BM and MF droplet methods by DLS revealed particle sizes that were 40–50% smaller 
for the microfluidic device with particles averaging close to 100 nm. The size distribution 
was also considerably narrower for the MF polyplexes compared to those produced by 
the conventional method. Polyplexes produced by MF and BM demonstrated PdI’s of 
0.152 and 0.342, respectively. In addition, it was shown that the particles were stable 
over a period of 240 min by demonstrating consistent particle sizes over the time period 
by DLS. In comparison, particles produced by BM nearly doubled in size over the same 
period, which is a strong indication of aggregation. Free cationic polymer is often present 
in BM polyplex formulations and is generally considered to be a problem due to its 
potential toxicity. Using PicoGreen and RiboGreen assays, it was show that using 
microfluidics in formulation of either DNA or RNA polyplexes resulted in less free 
polymer in the final product.  Primary mouse embryonic fibroblast (PMEF), human 
mesenchymal stem cells (hMSC), HepG2 human hepatocellular carcinoma cells and 
HEK293 human embryonic kidney cells were chosen to assess transfection and cellular 
uptake. With gains ranging from 6 to 31%, flow cytometry revealed that a larger fraction 
of cells was transfected by MF-produced polyplexes compared to conventional 
polyplexes. Total gene expression was measured by luciferase assay, and the same trend 
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was seen with 1.9- to 6.8-fold increases for the MF polyplexes compared to the 
conventional polyplexes. Additional flow cytometry experiments were carried out to 
assess the cellular uptake and trafficking of the polyplexes within the cells. By combining 
QD-FRET analysis and flow cytometry, the researchers observed that the MF-produced 
polyplexes stayed intact much longer than the readily unpacking BM polyplexes. They 
suggest that prolonged stability within the cell of polyplexes in the MF formulations 
could result in greater protection from degradation prior to endosomal escape. 
 
3.3 Conclusions 
Microfluidic devices have branched out of the realm of being used solely for 
sensing and analysis applications, and new applications in nanoprecipitation are being 
explored. Polymeric non-viral gene therapies are well-suited for these advanced 
nanoprecipitation devices due to day-to-day and experiment-to-experiment variations that 
are known issues for bulk-mixed polyplexes [45]. Employing the two primary MF mixing 
strategies of continuous hydrodynamic flow focusing and droplet generation, researchers 
have demonstrated the many advantages of using a lab-on-a-chip device for the 
production of polymeric gene delivery vectors. These advantages include the production 
of particles with narrower size distributions, lower cytotoxicity and higher transfection 
efficiencies. Additionally, the technique operates in a continuous fashion, which is a 
known advantage within the pharmaceutical field since the production of drugs can be 
easily standardized and the quality of the resulting product is more consistent [100]. 
Moving forward, MF devices have the potential for advancing the field of non-
viral gene delivery employing the techniques mentioned above. However, there are still 
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issues with the use of the devices and room for advancement. For example, all of the 
previously mentioned examples produce relatively simple polyplex nanoparticles that 
may not provide enough functionality to overcome all of the cellular barriers to delivery. 
These particles, therefore, may fall short of required cellular uptake and gene expression 
levels necessary to compete with viral vectors. One innovation that may allow for the 
advancements necessary to get closer to these positive attributes of viral vectors is the 
design of chips to produce more complicated non-viral vectors such as ternary 
polyplexes. 
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Chapter 4: Microfluidic Production of PEI/DNA Polyplexes with Separation of Free 
Polymer 
Polymeric gene delivery vectors offer a safer alternative to viral gene delivery. 
However, transfection efficiency remains low, and many polymers exhibit dose-limiting 
cytotoxicity. Conventional preparation of polyplexes by bulk mixing (BM) of polymers 
and DNA is a relatively uncontrolled process that leads to polydispersity of polyplex size 
and poor reproducibility. Alternatively, polyplexes may be prepared in microfluidic 
channels wherein polymers and DNA are brought into contact by diffusion, allowing 
better control of the process and leading to smaller and more uniform polyplexes. We 
have designed a microfluidic (MF) device for polyplex fabrication that has the capability 
of separating free polymer from the assembled particles, referred to as a microfluidic 
separator (MS). The transfection efficiency and cytotoxicity of BM and MS polyplexes 
comprising polyethylenimine (PEI) were compared in three model human cell lines: 
HeLa, U-87 MG and MDA-MB-231. MS polyplexes at 0.6:1 (w:w) PEI:DNA exhibited 
approximately 150-, 2.5-, and 7-fold increase in transgene expression compared to BM 
polyplexes in the three cell lines, respectively. MS polyplexes also exhibited a 30-, 11- 
and 20% increase in cell viability at 0.6:1 (w:w) PEI:DNA, compared to BM polyplexes 
at their optimal transfection ratio of 1.8 (w:w) PEI:DNA. MS polyplexes were also 60-
77% smaller than BM polyplexes. The results suggest that diffusion-controlled polyplex 
assembly and separation of excess PEI results in relatively efficient gene delivery at low 
PEI/DNA ratios where cytotoxicity is reduced, potentially allowing administration of a 
higher dose of DNA. Additionally, this approach for separation in a microfluidic device 
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may be important in preparing a variety of nanoparticle drug delivery systems by 
removing potentially toxic components and enabling the fabrication of more complex 
delivery systems. 
 
4.1 Introduction 
 Polymer-mediated gene delivery is of interest as a safer, more versatile alternative 
to viral vectors [45]. However, due to the relatively low delivery efficiency, instability in 
serum, and cytotoxicity associated with many gene delivery polymers, non-viral gene 
delivery vectors have had limited success in the clinic. Attempts to address the limitations 
of polymer-mediated gene delivery have largely focused on the chemistry of the 
materials. Strategies have included, for example, synthesizing biodegradable polymers 
with reduced cytotoxicity [101–105], conjugating cell-specific targeting moieties 
[93,106–108], designing copolymer hybrids [109–112] or other chemical modifications 
[7,113–115], and incorporating multiple polymers in a single vector [14,116–118].  
The methods most often used for assembly of polymer/DNA complexes 
(polyplexes) represent another limitation of polymeric vectors. Conventionally, 
polyplexes are generated by simply mixing aqueous solutions of the constituents in a 
small volume followed by a short incubation period (15-30 min) during which 
spontaneous, entropically driven self-assembly occurs between the polycation and the 
nucleic acid (referred to as bulk mixing, BM). Although simple and easily implemented, 
polyplexes formed by BM are often large (200-500 nm) and exhibit strongly positive zeta 
potential (+25-50 mV) due to the presence of excess polycation. Polyplex sizes can be 
controlled to some extent by varying the polymer/DNA ratio and solution conditions, but 
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size distributions are commonly heterogeneous. In addition, excess free polymer usually 
remains in the resulting suspension, contributing to cytotoxicity [119–121]. Finally, this 
uncontrolled process provides poor reproducibility from batch to batch and, especially, 
lab to lab and would hinder large-scale manufacture required for clinical translation 
[122,123]. 
The use of microfluidic (MF) devices for the assembly of polyplexes offers a 
continuous and potentially more reproducible alternative to BM [16–18,78]. Typically, a 
plasmid DNA solution is passed through a central channel while the polycation is 
introduced from each side to hydrodynamically focus the DNA solution into a narrow 
stream. Because of the small channel dimensions (~200 µm), the flow is laminar and no 
mixing occurs between the parallel streams. The polymer, however, can diffuse into the 
DNA-containing stream. Thus, the rate of the polymer/DNA interaction is diffusion 
controlled (~4D/L2; where D is polymer diffusivity and L is the width of the DNA-
containing stream) and can be manipulated by varying the channel dimensions and 
relative DNA and polymer solution flow rates, which govern the width of the polymer 
and DNA streams within the channels. Compared to conventional polyplexes formed by 
BM, MF-assembled polyplexes are typically smaller, more uniform and exhibit higher 
gene delivery activity [16,17].  
Several of the previously reported MF devices have employed channel lengths of 
<5 cm, cross sectional area of ~100x200 µm2 and flow rates of ~100 µL/min, 
corresponding to a residence time of material within the device of <1 sec. Assuming 
polycation diffusivity on the order of 10-6 cm2/sec and typical DNA-containing stream 
widths of 20-100 µm, the characteristic diffusion time (L2/4D) is expected to be 1-25 sec 
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[124], suggesting that there is insufficient time for diffusion of polymer from the outer 
stream to the center of the channel within the device, and polyplex formation may 
continue in the bulk after exiting the microfluidic channels. Here we report the design of 
MF devices for polyplex assembly with significantly longer channel lengths. In addition, 
complete formation of polyplexes within the channels provides an opportunity to separate 
free polycation from the polyplexes, which remain confined to the center channel due to 
their much larger size and, therefore, lower diffusivity. Removal of free polymer may 
provide reduced cytotoxicity.  
 
4.2 Materials and Methods 
 
4.2.1 Materials 
 Branched PEI with an average molecular weight of 25 kDa was purchased from 
Sigma-Aldrich and dissolved in phosphate buffered saline (PBS). Lipofectamine 2000 
transfection reagent was purchased from Thermo Fisher. Luciferase assay system and 
Cell Titer-Blue cell viability assay kit were purchased from Promega. Cellular lysis 
buffer was prepared as directed by the luciferase assay kit protocol. Luciferase plasmid 
(pGL3 control vector) was purchased from Elim Biopharmaceuticals. 
 
4.2.2 Computational Fluid Dynamics 
 To aid in the design of the MF device, the flow and diffusion within the channels 
was modeled using COMSOL Multiphysics version 4.3b with the microfluidics module. 
The diffusivity of the PEI was estimated using the Stokes-Einstein relation and 
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approximated to be 1.0x10-7 cm2/sec. Using the relation developed by Lukacs et al. the 
diffusivity of the plasmid DNA (5,217 bp, 2.98 MDa) was approximated to be 1.3x10-6 
cm2/sec [125]. 
 
4.2.3 Microfluidic Device Fabrication 
 Microfluidic devices were fabricated using well-established soft lithography 
techniques [126]. In short, channel designs were created in Autocad and printed onto a 
transparency to generate a photholithographic mask. A master mold was made using 
Microchem SU-8 3050 negative photoresist by adhering to the spin curves and processing 
suggested by Microchem. In short, glass slides were cleaned with acetone, ethanol and 
then water. The slides were then thoroughly dried with nitrogen and the photoresist was 
spincoated onto the slide and the depth was verified to be 100 µm with a profilometer. 
The slide and photoresist were then exposed to UV radiation in a mask aligner using the 
photolithographic mask. The slide and resist were then cured for an hour at 95 °C and 
then developed using Microchem SU-8 developer to yield the master mold. Dow Corning 
Sylgard 184 Silicone Encapsulant PDMS resin (Ellsworth Adhesives) was then applied to 
the master mold and cured in an oven at 100 °C for one hour. The PDMS containing the 
microchannels was then peeled from the mold and attached to a glass microscope slide 
using a Harrick Basic Plasma Cleaner PDC-32G-2. In all instances microfluidic channels 
are rectangular with a width of 200 µm and a depth of 100 µm. A microfluidic punch was 
used to create holes at the inlets and outlets of the device, and tubing was pressed directly 
into the holes. Tubes of equal length were used at all outlets to ensure that the resistance 
associated with each outlet was equal. 
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4.2.4 Flow Characterization 
Flow characterization experiments were carried out by flowing 500 kDa 
fluorescein-conjugated dextran (Sigma-Aldrich) through the DNA inlet and 70 kDa 
rhodamine-conjugated dextran (Sigma-Aldrich) through the PEI inlet. Images were 
obtained with a Labsmith SVM340 synchronized video microscope with fluorescence 
capabilities. 
 
4.2.5 Ninhydrin Assay 
Ninhydrin reagent (Sigma-Aldrich) was used according to the protocol provided 
by the manufacturer with modifications to accommodate PEI rather than amine 
containing proteins. Specifically, Nin – Sol was mixed with lithium acetate buffer in a 3:1 
volumetric ratio. Twenty microliters of both samples and standards were mixed with an 
equal volume of the reagent and incubated at 90 °C for 10 min. After the incubation 
period, samples and standard were diluted with 200 µL of ethanol and added to a clear 
96–well plate. The absorbance was read at a wavelength of 572 nm on a Biotek Synergy 
II plate reader. 
 
4.2.6 Polyethylenimine Labeling 
Polymers were labeled with Alexa Fluor 594 by mixing 1 mg of an Alexa Fluor 
NHS-ester in 200 µL of anhydrous DMSO with 10 mg of PEI in 1.8 mL of 0.2 M sodium 
carbonate, pH 9.3. The reaction was allowed to run for 12 h with gentle mixing at room 
temperature and shielded from light to prevent photobleaching. The labeled polymer was 
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separated from unreacted dye by dialysis using a Spectra Por dialysis tubing with 
molecular weight cutoff of 10 kDa against 4 L pure water exchanged three times over a 
24 h period. The resulting PEI-AF594 solution was lyophilized, weighed and then diluted 
into PBS to be used as a stock solution. Labeling density was determined to be 0.5 dyes 
per polymer chain. 
 
4.2.7 Preparation of Polyplexes and Lipoplexes 
BM polyplexes were generated using standard protocols. Briefly, DNA was 
diluted to 20 µg/mL in PBS at a pH of 6.8 and phosphate concentration of 0.0067 M. PEI 
was similarly diluted to appropriate concentrations to achieve the desired polymer:DNA 
ratio. Polyplexes were formed by pipetting 200 µL of PEI solution into a microcentrifuge 
tube containing an equal volume of DNA and mixed by briefly vortexing. Polyplexes 
were then incubated for 20 min at room temperature. Lipofectamine 2000/DNA 
complexes were formed according to the manufacturers protocol. Specifically 24 µL of 
Lipofectamine 2000 was diluted into 176 µL of Eagle’s Minimum Essential Media 
(EMEM) . An equal volume of DNA (20 µg/mL in PBS) was added to the Lipofectamine 
2000 solution and allowed to incubate for 5 min. For the production of polyplexes with 
MF devices, DNA was diluted to 15 µg/mL in PBS and PEI solutions were also prepared 
in PBS to provide the desired PEI:DNA ratios. The DNA and PEI solutions were pumped 
at a flow ratio of 0.2 (DNA flow rate/total flow rate) and at a total flow rate of 100 
µL/min, to yield a product with the final DNA concentration of 10 µg/mL. The resulting 
polyplexes were used immediately for characterization or transfection as described 
below. 
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4.2.8 Agarose Gel Electrophoresis 
The amount of free polymer in polyplex suspensions was determined by agarose 
gel electrophoresis. Polyplexes were prepared using PEI-AF594 either by BM or MF as 
described above. Samples of polyplexes and free PEI, each containing 50 µg PEI, were 
loaded into a 0.75% agarose gel and electrophoresed at 100 V for 30 min. The gel was 
imaged on a GE Typhoon FLA 7000 laser scanner and the amount of free polymer was 
determined by integration of the fluorescent bands. 
 
4.2.9 Transfections 
HeLa (human cervical carcinoma), U-87 MG (human glioblastoma) and MDA–
MB–231 (human breast carcinoma) cell lines were obtained from ATCC and cultured in 
Eagle’s minimum essential media (EMEM, ATCC) supplemented with 10% fetal bovine 
serum (VWR) at 37˚C and 5% CO2 according to ATCC protocols. All transfections were 
carried out using protocols well established within the research group. Cells were seeded 
in 12-well plates at 100,000 cells per well 24 h prior to transfection. Growth media was 
removed from the cells and replaced with 1.5 mL of polyplex suspension containing 1 µg 
DNA per well. After 4 h, polyplexes were removed and replaced with growth media. 
Luciferase expression was quantified 24 h post-transfection using the Promega luciferase 
assay system. Luciferase activity was measured using a Biotek Synergy II plate reader. 
Results were normalized to total protein concentration in the lysate quantified using BCA 
assay (Pierce, Rockford, IL) following the manufacturers protocol. 
 
61	
	
 
4.2.10 Cytotoxicity  
Cytotoxicity of BM and MF polyplexes was quantified using the Cell Titer-Blue 
viability assay (Promega). In short, cells were plated in 96-well tissue culture plates at 
20,000 cells per well and transfected 24 h later following the same transfection procedure 
as above, substituting 10 µL of polyplex solution to accommodate the smaller wells. At 
24 h post-transfection, 20 µL of the cell titer blue reagent was added to each well and 
incubated for 4 h. The fluorescence (ex 530 nm, em 590 nm) of each well was determined 
using a Biotek Synergy II plate reader.  
 
4.2.11 Particle Characterization 
Particle size, zeta potential and polydispersity were determined using a Malvern 
Zetasizer Nano ZS. Polplyexes were produced as described above. The resulting solution 
(400 µL) was then diluted by addition of 200 µL deionized water and immediately added 
to Malvern Folded Capillary Zeta Cell. Each measurement was performed in triplicate  
 
4.3 Results and Discussion 
4.3.1 Flow modeling and Channel Design 
To predict the appropriate channel geometry for the device, an initial design was 
modeled in COMSOL (Fig. 4.1A) and the concentration of DNA was calculated as a 
function of position along the channel cross-section and channel length at varying flow 
ratios (FR), which we define here as the ratio of the flow rate of the center stream to the  
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Figure 4.1: Initial channel design demonstrating the microfluidic channel geometry (A). 
DNA concentrations were determined computationally at various points along the 
channel and plotted as slices of the channel cross-section at those points. DNA cross-
sectional concentration profiles are shown immediately after introduction of the outer 
streams (dark blue) and at 25 cm downstream (cyan) at FR = 0.2 (B), 0.3 (C) and 0.5 (D). 
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total flowrate (Fig. 4.1B – 4.1D). At the various flow ratios, the model shows similar 
DNA diffusion behavior with the DNA remaining mostly confined to the center portion 
of the channel. This result suggests that by sheering away the outer, DNA-free portions of 
the stream, the polyplexes may be separated from free PEI. 
The concentration of PEI within the channels was also modeled at various values 
of FR. As expected due to the narrowing of the center DNA-containing stream, the PEI 
concentration in the center stream increased with decreasing FR (Fig. 4.2A). Lower flow 
ratios are more desirable in microfluidic nanoprecipitation as this leads to narrower DNA 
streams and often smaller average particle sizes [127]. It is also well known that there is a 
lower limit to the FR for a specific channel, below which flow of the center stream in the 
hydrodynamic focusing region is unstable due to the mechanics of the syringe pumps 
[128]. The lowest flow ratio that could provide stable flow in our device was found to be 
FR = 0.2 (data not shown). At this FR, the average concentration of PEI within the center 
stream is ~48% of the steady state concentration at 25 cm downstream (Fig. 4.2A) and is 
relatively uniform across the center stream (Fig. 2E). This information allows for the 
design of the separation mechanism as well as a good approximation of the appropriate 
inlet concentrations of DNA and PEI to achieve the desired polymer:DNA ratio in the 
polyplexes.  
 
4.3.2 Flow Characterization and Model Validation 
 The microfluidic system for introduction of PEI and DNA, flow focusing, 
a serpentine diffusion region, and separation of free PEI is shown in Fig. 4.3A-E. 
Fluorescein-labeled dextran (500 kDa) was used to simulate the DNA center stream along  
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Figure 4.2: CFD analysis of microfluidic geometries. (a) Average fractional concentration 
of PEI within the product stream, calculated by integrating the concentration of PEI over 
the cross-sectional area of the channel representing the separation region at the relevant 
channel length of 25 cm. (b) Cross-sectional view of the channel, giving the initial 
concentration profile of DNA. (c) Cross-sectional view of the channel, giving the 
concentration profile of DNA at 25 cm. (d) Cross-sectional view of the channel, giving 
the initial concentration profile of PEI. (e) Cross-sectional view of the channel, giving the 
concentration profile of PEI at 25 cm. 
 
 
 
 
 
 
Figure 4.3: Separation device schematic and flow characterization. (A) The design and 
schematic of a microfluidic separator. (B) The hydrodynamic focusing region of the 
device. (C) The separation region of the microfluidic device. (D) Zoomed in fluorescence 
image of the hydrodynamic focusing region. (E) Zoomed in fluorescence image of the 
separation region.  
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with water in the outer channels for visualization of the flow focusing and separation 
regions of the microfluidic channels. Fluorescence microscopy of the flow focusing 
region reveals narrowing of the center stream from the inlet channel width of 200 µm to 
40 µm, as expected at FR = 0.2 (Fig. 4.3D), creating two interfaces through which the 
PEI can diffuse into the center region of the channel. Fluorescence micrographs of the 
separation region show the center fluorescent portion of the stream continues on to the 
product outlet while the outer portions of the channel are separated to either side (Fig. 
4.3E). It may appear that some of the outer stream continues to the center product stream 
after the separation. However, the intensity of the fluorescein emission decreases quickly 
as the fluorescein concentration decreases across the channel cross section, making it 
difficult to visualize the dextran at low concentrations at the edge of the center stream.  
To validate the modeling results and evaluate the performance of the separation 
mechanism, PEI concentration in the outlet was quantified and compared to the inlet PEI 
concentration. PEI was pumped through the side channels of the MS device at 
concentrations ranging from 2 to 12 µg/mL, along with water through the center inlet at 
FR = 0.2. The concentration of PEI in the center stream after separation was 46.1% of the 
inlet concentration, which is in close agreement with the computational models described 
above [A.1]. This result suggests that only PEI that has diffused into the center channel is 
recovered in the product. In a separate experiment, DNA (15 µg/mL) was pumped 
through the center channel with water in the side channels at FR = 0.2. The outlet 
concentration of the DNA was determined to be 9.7 ± 0.57 µg/mL (n = 13), while the 
model predicts 10 µg/mL, further validating the model and indicating that the separation 
was achieved as expected. 
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4.3.3 Microfluidic Polyplex Formation and Characterization 
Polyplexes were fabricated by conventional BM and the MS device, and the sizes 
of the resulting polyplexes were compared at PEI/DNA ratios of 0.6:1 to 3.0:1 (w:w) 
(Fig. 4.4A). The minimum size of BM polyplexes was ~200 nm at PEI/DNA ratio of 
2.5:1 (w:w), while the smallest MS polyplexes were 170 nm at PEI/DNA ratio of 1.8:1 
(w:w). At PEI/DNA ratio of 0.6:1 (w:w), BM polyplexes were >1 µm, likely due to 
aggregation, while MS polyplexes were only ~340 nm. Little difference in polydispersity 
of BM and MS polyplexes was observed at PEI/DNA ratios of 1.8:1 (w:w) or less, but the 
MS polyplexes were significantly less polydisperse at DNA/PEI 2.4:1 and 3.0:1 (w:w) 
(Fig. 4.4B). Finally, polyplex zeta potentials were ~10 mV at PEI/DNA 0.6:1 (w:w) and 
increased to ~15-20 mV at higher PEI/DNA ratios (Fig. 4.4C). The zeta potential of MS 
polyplexes was generally more positive than BM polyplexes, but the differences were not 
statistically significant. 
 
4.3.4 Determination of Free PEI in Polyplex Suspensions 
The amount of free polymer present in either BM or MS polyplex formulations 
may be important since free PEI is known to be cytotoxic [129]. We were interested in 
comparing the separation device with not only BM particles, but also polyplexes 
produced by a microfluidic device similar to those previously reported by other groups 
(with a 2 cm channel for diffusion, MF2) and another device that has the same 25-cm  
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Figure 4.4: Comparison of physicochemical properties of polyplexes produced by 
different methods. Average particle size (A), size polydispersity (B), and zeta-potential 
(C) of PEI/DNA polyplexes produced either by BM or MS techniques over a range of 
W:W’s. Error bars represent the mean ± S.E.M. (n=3). *P<0.05 and **P<0.01 for MS 
compared to BM polyplexes. 
	
	
	
	
.  
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channel length as the MS device but no separation mechanism (MF25) [A.2A-A.2B] 
Comparing devices of different channel lengths demonstrates the role of mixing time in 
the production of polyplexes. The fraction of free PEI in BM, MS, MF25 and MF2 
polyplex suspensions was determined by gel electrophoresis of polyplexes prepared with 
a fluorescently labeled PEI (PEI-AF594). This method allows for separation of the free 
PEI, free DNA and polyplexes. Free DNA migrates toward the cathode, polyplexes are 
likely too big to migrate and remain in the loading well, and the free polymer is 
positively charged and migrates toward the anode. By comparing the band intensities of 
free PEI-AF594 resulting from electrophoresis of PEI only and PEI/DNA polyplex 
suspensions, we can determine the amount of free polymer in the polyplexes (Fig. 4.5A).  
Polyplex suspensions produced at PEI/DNA ratio of 1.8:1 (w:w) contained 57, 42, 
34 and 25% free PEI for BM, MF2, MF25, and MS devices, respectively (Fig. 4.5B). 
Significantly less free PEI was observed in MS polyplexes compared to BM polyplexes, 
confirming that the separation mechanism allows for the separation of free polymer that 
is present in the side channels of the MS device. Additionally, MF2 polyplexes contained 
a larger amount of free PEI compared to MF25 polyplexes, further suggesting that the 
MF2 device and similar systems do not allow sufficient time for complete interaction of 
the PEI and DNA.  
 
4.3.5 Transfection with BM and MS Polyplexes 
Initial transfections were carried out over PEI/DNA ratios from 0.6:1 to 3.0:1 
(w:w) for both BM and MS polyplexes in three model human cells lines: U-87 MG, 
glioblastoma; HeLa, cervical adenocarcinoma; and MDA–MB–231, breast  
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Figure 4.5: Determination of free PEI by agarose gel electrophoresis. (a) PEI-AF594 
fluorescence in an agarose gel showing bands representing free PEI in samples of 
polyplexes (BM, MS, MF25 and MF2) and polymer only without DNA (PEI). (b) PEI-
AF594 fluorescence intensities integrated over the area of the bands as a ratio to 
integrated band intensities of PEI only. Error bars represent the mean  ± S.E.M. (n=3). 
*P<0.05 and **P<0.01 for sample compared to BM polyplexes   
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adenocarinoma. Upon transfection with BM polyplexes, the maximum transgene 
expression was observed at DNA/PEI ratio of 1.8:1 (w:w) for all three cell lines. For 
transfections with MS polyplexes, maxima were observed at PEI/DNA ratio of 1.8:1 
(w:w) in U-87 MG and HeLa cells, and 1.2:1 (w:w) in MDA–MB–231 cells (Fig. 4.6). 
Although transfection activities of MS and BM polyplexes were similar at their 
respective maximal PEI/DNA ratios, with only transfections carried out in the HeLa cells 
exhibiting statistically significant increases in transfection efficiency, MS polyplexes 
exhibited slightly higher average transfection activity in most cases. Importantly, 
transfections with MS polyplexes were significantly more efficient than BM polyplexes 
at PEI/DNA = 0.6:1 (w:w), where MS polyplexes exhibited 325-, 1.5- and 6-fold 
increases in normalized transfection activity in comparison to BM polyplexes in U-87 
MG, HeLa, and MDA–MD–231 cell lines, respectively. This result suggests that MS 
polyplexes at low PEI/DNA ratios may provide efficient transfection with less 
cytotoxicity, potentially allowing administration of a higher dose.  
 
4.3.6 Cytotoxicity of BM and MS Polyplexes 
To investigate the potential cytotoxicity of differing amounts of free PEI in BM 
and MS polyplexes, each of the three cell lines was transfected at various PEI/DNA ratios 
and cellular metabolic activity was assayed. Metabolic activity of all three cell lines 
decreased ~20-60% following transfections with no clear trend in cytotoxicity with 
PEI/DNA ratio. This may be due to the difference in amounts of free PEI at the varying 
PEI/DNA ratios. In general, cells transfected with MS polyplexes exhibited less 
cytotoxicity compared to those transfected with BM polyplexes, though the differences  
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Figure 4.6: Gene expression in three cell lines. Transfection of (A) HeLa, (B) U-87 MG, 
and (C) MDA-MB-231 cells by PEI/DNA polyplexes assembled by bulk mixing (BM) 
and the microfluidic device with separation (MS). Transfection efficiency is expressed as 
luciferase activity mediated by polyplex transfection normalized to luciferase activity 
mediated by transfection mediated by Lipofectamine 2000 carried out at the same time. 
Error bars represent the mean  ± S.E.M (n=3). *P<0.05 and **P<0.01 for MS compared 
to BM polyplexes at the same PEI/DNA ratio. 
 
	
	
 
 
Figure 4.7: Cell viability of transfected cells. Metabolic acitivity of (A) HeLa, (B) U-87 
MG, and (C) MDA-MB-231 cells following transfection with BM and MS PEI/DNA 
polyplexes and Lipofectamine 2000 (L) normalized to metabolic activity of untreated 
cells. Error bars represent the mean  ± S.E.M (n=3). *P<0.05 and **P<0.01 for MS 
compared to BM polyplexes at the same PEI/DNA ratio   
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were not statistically significant in many instances (Figure 4.7). It appears likely that the 
reduced cytotoxicity of MS polyplexes is the result of significantly less free PEI in these 
formulations, as described above.  
 
4.4 Conclusions 
In summary, a microfluidic device employing a unique separation mechanism was 
used to fabricate PEI/DNA polyplexes for the delivery of nucleic acids. Mathematical 
modeling of the flow characteristics and diffusion of polymer in the device allowed 
prediction of fabrication parameters and inlet concentrations to produce polyplexes at 
desired PEI/DNA ratios and to effectively separate free PEI from the formed polyplexes. 
Our results indicate that the MS produced polyplexes not only have smaller particle sizes 
at lower PEI/DNA ratios, but additionally demonstrate enhanced transfection activity and 
lower cytotoxicity in comparison to polyplexes produced via BM. Additionally, the 
separation mechanism may allow for the production of more complex polyplex systems, 
such as layer-by-layer assembly of ternary polyanion/polycation/DNA polyplexes, which 
will be the subject of further investigation. 
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Chapter 5: Steps Towards Microfluidic Separation for the Production of Ternary 
Polyplexes 
 In this chapter, we will review experiments that demonstrate support for the use of 
the MS device for the production of ternary polyplexes. As throughout the manuscript, 
the primary focus of the research is the development of polymer-based non-viral gene 
delivery vectors that are clinically and commercially viable. Since in Chapter 4 we 
showed that MS-produced polyplexes demonstrated significant transfection efficiencies 
at lower PEI/DNA ratios, in this chapter we explore the effect of increasing the total dose 
of PEI/DNA polyplexes at these ratios in MS- and BM-produced polyplexes. After 
establishing the need for a more complex polymer system to advance towards clinical 
implementation, we will explore optimum molecular weights of PGA for use in 
transfections. As stated previously, it is unclear what molecular weights were used by 
Kurosaki et al [48].  
 
5.1 Materials and Methods 
 
5.1.1 Materials 
 Branched PEI with an average molecular weight of 25 kDa was purchased from 
Sigma-Aldrich and dissolved in phosphate buffered saline (PBS). PGA was purchased 
from Alamanda Polymers with molecular weights of 7.5, 15, and 30 kDa. Lipofectamine 
2000 transfection reagent was purchased from Thermo Fisher. Luciferase assay system 
and Cell Titer-Blue cell viability assay kit were purchased from Promega. Cellular lysis 
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buffer was prepared as directed by the luciferase assay kit protocol. Luciferase plasmid 
(pGL3 control vector) was purchased from Elim Biopharmaceuticals.  
 
5.1.2 Microfluidic Device Fabrication 
Microfluidic devices were fabricated using well-established soft lithography 
techniques [126]. In short, channel designs were created in Autocad and printed onto a 
transparency to generate a photholithographic mask. A master mold was made using 
Microchem SU-8 3050 negative photoresist by adhering to the spin curves and processing 
suggested by Microchem. In short, glass slides were cleaned with acetone, ethanol and 
then water. The slides were then thoroughly dried with nitrogen and the photoresist was 
spincoated onto the slide. The depth was verified to be 100 µm with a profilometer. The 
slide and photoresist were then exposed to UV radiation in a mask aligner using the 
photolithographic mask. The slide and resist were cured for 1 h at 95 °C and then 
developed using Microchem SU-8 developer to yield the master mold. Dow Corning 
Sylgard 184 Silicone Encapsulant PDMS resin (Ellsworth Adhesives) was applied to the 
master mold and cured in an oven at 100 °C for 1 h. The PDMS containing the 
microchannels was peeled from the mold and attached to a glass microscope slide using a 
Harrick Basic Plasma Cleaner PDC-32G-2. In all instances microfluidic channels are 
rectangular with a width of 200 µm and a depth of 100 µm. A microfluidic punch was 
used to create holes at the inlets and outlets of the device, and tubing was pressed directly 
into the holes. Tubes of equal length were used at all outlets to ensure that the resistance 
associated with each outlet was equal. 
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5.1.3 Preparation of Polyplexes and Lipoplexes 
 BM polyplexes were generated using standard protocols. Briefly, DNA was 
diluted to 20 µg/mL in PBS at pH 6.8 and 0.0067 M phosphate. PEI was similarly diluted 
to appropriate concentrations to achieve the desired PEI:DNA ratio. Polyplexes were 
formed by pipetting 200 µL of PEI solution into a microcentrifuge tube containing an 
equal volume of DNA and mixed by briefly vortexing. Polyplexes were incubated for 20 
min at room temperature. Lipofectamine 2000/DNA complexes were formed according 
to the manufacturers protocol. Specifically, 24 µL of Lipofectamine 2000 was diluted 
into 176 µL of Eagle’s Minimum Essential Media (EMEM, ATCC). An equal volume of 
DNA (20 µg/mL in PBS) was added to the Lipofectamine 2000 solution and allowed to 
incubate for 5 min. For the production of binary polyplexes with MF devices, DNA was 
diluted to 50 µg/mL in PBS and PEI solutions were also prepared in PBS to provide the 
desired PEI:DNA ratios. The DNA and PEI solutions were pumped at a flow ratio of 0.2 
(DNA flow rate/total flow rate) and at a total flow rate of 100 µL/min, to yield a product 
with the final DNA concentration of 10 µg/mL. For the production of ternary polyplexes 
with the MF device, a polyanionic solution of DNA and PGA was first created where the 
final concentration of DNA was 50 µg/mL and that of PGA was 60 µg/mL. The 
polyanionic and PEI solutions were pumped at a flow ratio of 0.2 (DNA flow rate/total 
flow rate) and at a total flow rate of 100 µL/min, to yield a product with the final DNA 
concentration of 10 µg/mL. 
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5.1.4 Transfections 
 HeLa (human cervical carcinoma) cells were obtained from ATCC and cultured 
in EMEM supplemented with 10% fetal bovine serum (VWR) at 37˚C and 5% CO2 
according to ATCC protocols. All transfections were carried out using protocols well 
established within the research group. Cells were seeded in 12-well plates at 100,000 
cells per well 24 h prior to transfection. Growth media was removed from the cells and 
replaced with 1.5 mL of polyplex suspension containing 1 µg DNA per well. After 4 h, 
polyplexes were removed and replaced with growth media. Luciferase expression was 
quantified 24 h post-transfection using the Promega luciferase assay system. Luciferase 
activity was measured using a Biotek Synergy II plate reader. Results were normalized to 
total protein concentration in the lysate quantified using BCA assay (Pierce, Rockford, 
IL) following the manufacturers protocol. 
 
5.1.5 Cytotoxicity 
 Cytotoxicity of BM and MF polyplexes was quantified using the Cell Titer-Blue 
viability assay (Promega). In short, cells were plated in 96-well tissue culture plates at 
20,000 cells per well and transfected 24 h later following the same transfection procedure 
as above, substituting 10 µL of polyplex solution to accommodate the smaller wells. At 
24 h post-transfection, 20 µL of the Cell Titer-Blue reagent was added to each well and 
incubated for 4 h. The fluorescence (ex 530 nm, em 590 nm) of each well was determined 
using a Biotek Synergy II plate reader. 
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5.2 Results 
 
5.2.1 Dose Increase Experiments 
 To assess whether or not there would be an advantage in increasing the dose of 
binary polyplexes produced by microfluidics versus polyplexes produced by BM, we 
transfected HeLa cells produced by either method at a PEI/DNA weight ratio of 1.2 and 
at 1-, 3-, and 5-fold dose increases of DNA [Fig. 5.1]. Gene expression as assessed by 
luciferase assay indicated that there was more than a 10-fold increase in transgene  
expression for both BM and MS produced polyplexes at the highest dose in comparison 
to the standard dose of DNA. Cell viability experiments revealed that as the dose of DNA 
increased for either polyplex formulation method, cell viability also increased. In the case 
of BM-produced polyplexes, the viability increased from ~80% at the standard dose to 
~98% at the 5X dose.  For the case of MS-produced polyplexes, the viability increased 
from ~96% at the standard DNA dose to ~100% at the 5X dose.  
 
5.2.2 Optimizing PGA Molecular Weight for Polyplex Formulations and Probing 
Premixed Polyanions for TP Production 
 To optimize for PGA molecular weight, a set of transfections was carried out in 
HeLa cells to determine the transgene expression mediated by TPs comprising PEI, 
DNA, and PGA of three molecular weights – 7.5, 15, and 30 kDa. TPs were formulated 
both by bulk mixing and MF mixing in the 2MF channel [4.3.4] [Fig. 5.2]. Importantly in 
the case of the 2MF device the DNA and PGA are premixed and then the mixture is 
pumped through the device where and the PEI is introduced.  This experiment serves to  
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Figure 5.1: Transfections of HeLa cells carried out at 1-, 3-, and 5-times the standard 
dose of 1 µg of DNA with TPs produced either by BM or MS methods. The gene 
expression activity (A) and cell viability (B) of each transfection dose are reported. Error 
bars represent the mean  ± S.E.M. (n=3). *P<0.05 and **P<0.01 for MS compared to BM 
polyplexes.	
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Figure 5.2: Comparing transfections of HeLa cells with TPs formed by BM and the 2MF 
device in serum free media (A) and media containing serum (B). PEI/DNA ratio is set to 
1.8 throughout and the PGA/DNA ratio is set to 1.2 where applicable.	 Error bars 
represent the mean  ± S.E.M. (n=3). *P<0.05 and **P<0.01 for 2MF compared to BM 
polyplexes.  
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demonstrate whether or not the Wang mixing method [Fig. 5.3], where PGA and DNA 
are premixed and PEI is then added to the resulting mixture, is advantageous for the 
microfluidic production of polyplexes in comparison to conventional BM polyplexes 
[13]. The experiments were carried out both in serum-free media and media containing 
serum at a PEI/DNA weight ratio of 1.8 and a PGA/DNA weight ratio of 1.2. In the case 
of the BM formulations, transfections carried out in serum-free media showed no 
significant difference in transgene expression between polyplexes containing PGA of 
different molecular weights [Fig. 5.2A]. For the MF formulation method, transfections 
carried out in serum-free media showed ~30-fold decrease in transfection efficiency for 
TPs comprised of 7.5 kDa PGA compared to 15 and 30 kDa PGA [Fig. 5.2A]. TPs 
comprised of the two larger molecular weight PGA demonstrated gene expression with 
no significant difference between the gene expression of the two formulation methods 
[Fig. 5.2A]. Similar results were noted in the case of transfections carried out in media 
containing serum, with BM formulations demonstrating no difference in gene expression 
levels over the range of PGA molecular weights and MF formulations exhibiting a 200-
fold decrease in gene expression for 7.5 kDa PGA, and no significant difference between 
the other two PGA molecular weights [Fig. 5.2A]. 
 
5.3 Discussion 
 Previous reports of MF-produced polyplexes suggested that, since higher gene 
delivery efficiency was noted at lower polymer/DNA ratios and higher toxicity is 
associated with excess PEI, MF production of binary polyplexes followed by transfecting 
cells with a higher dose of the MF-produced polyplexes might provide an avenue to  
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Figure 5.3: Schematic of the mixing method used by Wang et al. where DNA and PGA 
are premixed and the resulting anionic solution is mixed with PEI to produce TPs. 
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increase gene delivery efficiency while simultaneously mitigating cytotoxicity [16]. Our 
results confirm that MF-produced polyplexes tend to allow for significantly increased 
transfection at these low doses compared to BM-produced polyplexes. However, when 
comparing polyplexes produced by the two methods, there was no difference in 
cytotoxicity at the higher doses. This result suggests that while MF production of 
polyplexes does provide an enhancement to transfection at low doses, the additional 
advantage of decreased cytotoxicity is not present.  
 Seeking to shed light on the effect of PGA molecular weight on TP transfection 
activity, we optimized transfections for PGA molecular weight for two different mixing 
methods both in serum-free media and media containing serum. In this case it was noted 
that PGA molecular weight seemed to have no effect on polyplex transfection activity of 
BM polyplexes. However, in the case of MF mixing it was shown that lower molecular 
weight PGAs performed poorly, demonstrating decreased transfection activity. Due to 
these results, further experimentation with TPs produced by microfluidic systems will 
employ PGA with a molecular weight of 15 kDa. Additionally, it was shown that 
combining the Wang TP mixing method and fabricating the polyplexes in a device 
similar to that used by Koh et al. led to no enhancement of gene transfection activity, a 
result that suggests that further device development would be necessary for the MF 
production of TPs.  
 
5.4 Conclusions 
 In this chapter, we explored the effect of dose increases on gene delivery levels in 
HeLa cells transfected with binary polyplexes produced by two different methods. It was 
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shown that while enhanced transgene expression was observed at standard doses of the 
polyplexes, increased dosing showed no advantage in terms of cellular toxicity. It was 
also shown that transfecting with TPs produced by PGAs of varying molecular weights 
had a minimal impact on transgene expression associated with TPs produced by BM. In 
the case of MF-produced TPs, however, we presented strong evidence suggesting that a 
PGA with molecular weights of 15 kDa or above would be better for increased 
transfection activity. Finally, while it is tempting to directly employ the Wang mixing 
method for TP production and Koh device for polyplex assembly, combining these two 
methods gave no advantage in terms of gene delivery efficiency. 
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Chapter 6: Assembly of Charge-Shielding Polyglutamic acid/Polyethylenimine/DNA 
Ternary Polyplexes in a Microfluidic Device 
 Ternary polyanion/polycation/DNA polyplexes provide advantages over more 
conventional binary polyplexes by allowing for increased stability of the polyplexes in 
serum through reduced interactions with proteins that are prevalent in the media. These 
vectors, however, are still limited by low gene delivery efficiency and batch to batch 
variation when the vectors are produced by conventional methods.  To improve the 
effectiveness of non-viral gene delivery vectors, ternary polyplexes were fabricated 
through the use of microfluidic devices. Comprised of plasmid DNA (DNA), 
polyethyleneimine (PEI) and α-polyglutamic acid (PGA), the vectors have demonstrated 
charge shielding and cell-targeting properties enabling prolonged stability in serum 
containing media and thus enhanced transfection efficiencies in these environments. Here 
we have developed a microfluidic separator (MS) capable of separating free PEI from 
polyplexes and sequential microfluidic mixer (SMF) for introducing polymers of 
alternating charge in sequence. The use of a MS in the production of the polyplexes is 
shown here to increase transfection activity by 24- and 35-fold in comparison to either 
conventional bulk mixing (BM) or a sequential microfluidic mixer (SMF) methodologies 
in MDA-MB-231 cells at an optimized PGA/DNA weight ratio of 1.2. A key result is the 
removal of free PEI with the MS system and thus the removal PEI/PGA “ghost” particles 
from the mixture, which exhibit no transfection activity due to their lack of genetic 
material.  
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6.1 Introduction 
 By allowing for the production of therapeutic proteins at affected tissue sites and 
other relevant locations throughout the body, gene therapy shows considerable promise as 
a treatment for many diseases [130]. Researchers have explored a variety of gene delivery 
vectors in search of the ideal delivery method, which would exhibit high gene delivery 
efficiency while simultaneously being shown to be safe. By packaging genetic material 
with recombinant viruses [36], cationic polymers [45], lipids [43], metallic nanoparticles 
[62], and combinations of the above [131,132], a variety of vectors have been produced. 
Cationic polymers, such as PEI, form complexes with DNA, which have been shown to 
protect the DNA from enzymatic degradation, associate with cellular membrane, and 
allow for endosomal escape through the proton sponge effect [1].  
Poor serum stability, however, is still a significant issue negatively impacting the 
clinical implementation of cationic non-viral vectors since it hinders systemic 
administration of the drugs. Aggregation due to association with negatively charged 
serum proteins leads to large particles, which demonstrate poor transfection ability in a 
wide variety of cell lines in vitro as well as mouse models in vivo [13]. Charge shielding, 
accomplished by coating a polyplex with a biocompatible polyanion, hinders binding of 
serum proteins and the resulting aggregation, thus maintaining transfection ability of 
polyplexes in serum-containing media as well as in vivo.  In addition to charge shielding, 
ternary polyplexes (TPs) allow for the creation of more complex vectors that can 
overcome multiple barriers to cell delivery. Important mechanisms that enable the vectors 
to overcome cellular barriers to delivery that have been demonstrated include charge 
conversion [51,52], membrane disruption [14], cell-specific targeting [64,66], pH- and 
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light-induced chemical bond degradation [57,59] and some combinations of the above 
[55,67]. With broad applicability to enhance non-viral gene therapy, TPs present an 
opportunity to move non-viral vectors toward clinical viability. 
A significant problem facing assembly of TPs and conventional polyplexes is the 
variability associated with mixing of the constituent materials. For example, Wang et al. 
[13] and Kurosaki et al. [48] report widely varying particle sizes for two PGA/PEI/DNA 
polyplex systems. Microfluidic hydrodynamic flow focusing has been demonstrated as 
potential method for standardizing vector formulation and allowing for consistent 
polyplexes from batch-to-batch and also between different labs [16,17]. In Chapter 3, I 
described the design, fabrication, and validation of a microfluidic system for the 
production of conventional PEI/DNA polyplexes and importantly the removal of free PEI 
from the product. 
Here we report the first use, to our knowledge, of a microfluidic system for the 
production of ternary polyplexes. By comparing polyplexes produced by bulk mixing 
(BM), by a microfluidic device capable of separating free PEI from polyplexes  (MS), 
and sequential microfluidic diffusive mixing (SMF) where PEI and PGA are 
hydrodynamically focused with DNA in sequence, we demonstrate the advantages of 
using MS in the production of PGA/PEI/DNA ternary polyplexes. We will compare the 
transfection efficiency, physicochemical properties, and toxicity of polyplexes produced 
by each method in serum free and serum-containing media. We will additionally probe 
cellular uptake and analyze the resulting ghost particle concentration for each method.  
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6.2 Materials and Methods 
 
6.2.1 Materials 
Branched PEI with an average molecular weight of 25 kDa was purchased from 
Sigma-Aldrich and dissolved in phosphate buffered saline (PBS). PGA with a molecular 
weight of 15 kDa was purchased from Alamanda Polymers. Lipofectamine 2000 
transfection reagent was purchased from Thermo Fisher. Luciferase assay system and 
Cell Titer-Blue cell viability assay kit were purchased from Promega. Luciferase plasmid 
(pGL3 control vector) was purchased from Elim Biopharmaceuticals. 
 
6.2.2 Microfluidic Device Fabrication 
Microfluidic devices were fabricated using well-established soft lithography 
techniques [126]. In short, channel designs were created in Autocad and printed onto a 
transparency to generate a photholithographic mask. A master mold was made using 
Microchem SU-8 3050 negative photoresist by adhering to the spin curves and processing 
suggested by Microchem. In short, glass slides were cleaned with acetone, ethanol and 
then water. The slides were then thoroughly dried with nitrogen and the photoresist was 
spincoated onto the slide and the depth was verified to be 100 µm with a profilometer. 
The slide and photoresist were then exposed to UV radiation in a mask aligner using the 
photolithographic mask. The slide and resist were then cured for an hour at 95 °C and 
then developed using Microchem SU-8 developer to yield the master mold. Dow Corning 
Sylgard 184 Silicone Encapsulant PDMS resin (Ellsworth Adhesives) was then applied to 
the master mold and cured in an oven at 100 °C for one hour. The PDMS containing the 
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microchannels was then peeled from the mold and attached to a glass microscope slide 
using a Harrick Basic Plasma Cleaner PDC-32G-2. In all instances microfluidic channels 
are rectangular with a width of 200 µm and a depth of 100 µm. A microfluidic punch was 
used to create holes at the inlets and outlets of the device, and tubing was pressed directly 
into the holes. Tubes of equal length were used at all outlets to ensure that the resistance 
associated with each outlet was equal. 
 
6.2.3 Preparation of Polyplexes and Lipoplexes 
BM polyplexes were generated using standard protocols. Briefly, DNA was 
diluted to 30 µg/mL in PBS (6.7 mM phosphate, pH 6,8). PEI was diluted to 54 µg/mL to 
yield PEI/DNA polyplexes at a PEI/DNA ratio of 1.8 (w:w). PGA was similarly diluted 
to appropriate concentrations to achieve the desired polymer:DNA ratios. Polyplexes 
were formed by pipetting 200 µL of PEI solution into a microcentrifuge tube containing 
an equal volume of DNA and mixing briefly by vortexing. Polyplexes were then 
incubated for 20 min at room temperature. After the incubation period, 200 µL of PGA 
was added to the PEI/DNA polyplex solutions at appropriate concentrations to achieve 
the desired PGA/PEI/DNA ratios. Lipofectamine 2000/DNA lipoplexes were formed 
according to the manufacturer’s protocol. Specifically, 24 µL of Lipofectamine 2000 was 
diluted into 176 µL of Eagle’s Minimum Essential Media (EMEM). An equal volume of 
DNA (20 µg/mL in PBS) was added to the Lipofectamine 2000 solution and allowed to 
incubate for 5 min.  
For the production of polyplexes with the MS device, DNA was diluted to 22.5 
µg/mL in PBS and PEI solutions were also prepared in PBS at a concentration of 40.5 
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µg/mL. The DNA and PEI solutions were pumped at a flow ratio of 0.2 (DNA flow 
rate/total flow rate) and at a total flow rate of 100 µL/min, to yield a 400 µL of product 
with the final DNA concentration at 15 µg/mL. The resulting polyplexes were 
immediately mixed with 200 µL of PGA at the appropriate concentrations to achieve the 
desired PGA/PEI/DNA ratios, final DNA concentration of 10 µg/mL, and allowed to 
incubate for 20 min at room temperature. For the production of polyplexes with the SMF 
device, initial DNA dilutions were made in PBS at a concentration of 200 µg/mL and 
initial PEI dilutions were made at a concentration of 112.5 µg/mL. The DNA was 
pumped at a flow rate of 20 µL/min, the PEI solution was pumped at a rate of 80 µL/min 
and the PGA solution was pumped at a rate of 400 µL/min resulting in two hydrodynamic 
focusing regions both at FR = 0.2. The final DNA concentration in this case was also 10 
µg/mL. 
 
6.2.4 Transfections 
HeLa (human cervical carcinoma), U-87 MG (human glioblastoma) and MDA–
MB–231 (human breast carcinoma) cell lines were obtained from ATCC and cultured in 
Eagle’s minimum essential media (EMEM, ATCC) supplemented with 10% fetal bovine 
serum (VWR) at 37 ˚C and 5% CO2 according to ATCC protocols. All transfections were 
carried out using protocols well established within the research group. Cells were seeded 
in 24-well plates at 200,000 cells per well 24 h prior to transfection. Growth media was 
removed from the cells and replaced with 1.5 mL of polyplex suspension containing 1 µg 
DNA per well. After 4 h, polyplexes were removed and replaced with growth media. 
Luciferase expression was quantified 24 h post-transfection using the Promega luciferase 
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assay system. Luciferase activity was measured using a Biotek Synergy II plate reader. 
Results were normalized to total protein concentration in the lysate quantified using BCA 
assay (Pierce, Rockford, IL) following the manufacturers protocol. In the case of 
transfections carried out in media containing serum, the same procedure as above was 
followed but with serum containing media throughout. 
 
6.2.5 Polyethylenimine Labeling 
Polymers were labeled with Alexa Fluor 488 by mixing 1 mg of an Alexa Fluor 
NHS-ester in 200 µL of anhydrous DMSO with 10 mg of PEI in 1.8 mL of 0.2 M sodium 
carbonate, pH 9.3. The reaction was allowed to run for 12 h with gentle mixing at room 
temperature and shielded from light to prevent photobleaching. The labeled polymer was 
separated from unreacted dye by dialysis using a Spectra Por dialysis tubing with 
molecular weight cutoff of 10 kDa against 4 L pure water exchanged three times over a 
24 h period. The resulting PEI-AF488 solution was lyophilized, weighed and then diluted 
into PBS to be used as a stock solution. Labeling density was determined to be 0.5 dyes 
per polymer chain. 
 
6.2.6 Cytotoxicity 
Cytotoxicity of BM and MF polyplexes was quantified using the Cell Titer-Blue 
viability assay (Promega). In short, cells were plated in 96-well tissue culture plates at 
20,000 cells per well and transfected 24 h later following the same transfection procedure 
as above, substituting 10 µL of polyplex solution to accommodate the smaller wells. At 
24 h post-transfection, 20 µL of the cell titer blue reagent was added to each well and 
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incubated for 4 h. The fluorescence (ex 530 nm, em 590 nm) of each well was determined 
using a Biotek Synergy II plate reader.  
 
6.2.7 Particle Characterization 
Particle size, zeta potential and polydispersity were determined using a Malvern 
Zetasizer Nano ZS. Polplyexes were produced as described above. The resulting solution 
(600 µL) was then diluted by addition of 300 µL deionized water and immediately added 
to Malvern Folded Capillary Zeta Cell. Each measurement was performed in triplicate. 
 
6.2.8 Flow Cytometry 
Plasmid DNA was first incubated with YOYO-1 at a volume/weight ratio of 15 
nL YOYO-1 per 1 µg of DNA at 4 °C for 30 min. Ternary polyplexes were formed with 
both alexa-labeled and unlabeled PEI, unlabeled PGA, and YOYO-1 intercalated DNA 
using each of the three methods described above (BM, SMF, MS). Each of the three cell 
lines were cultured as described above and plated in 24-well plates at 7.5x104 cells/well 
24 h prior to transfection. 50 µL of polyplex solution was then added to vials containing 
700 µL of either serum-free or serum-containing media and the resulting solution was 
then added to each well resulting in 0.5 µg plasmid/well. To remove surface-bound 
polyplexes, the cells were rinsed twice with 0.001% SDS in PBS and PBS two hours after 
transfection. 250 µL of 0.05% trypsin in PBS was then added to each well and the cells 
and trypsin were allowed to incubate for 5 min. After the cells were dislodged from the 
plate, 50 µL of FBS was added to each well and the cells were centrifuged at 6400 rpm 
for 5 min. The supernatant was aspirated and discarded, after which the resulting cell 
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pellet was resuspended in 1 mL of PBS. Each of the samples was then placed in a 15 mL 
centrifuge tube and ready for FACS analysis by an Attune flow cytometer and the data 
was processed using FloJo software. 
 
6.2.9 Fluorescence Correlation Spectroscopy (FCS) 
Employing a commercial dual-channel confocal spectrometer (ALBA FFS 
system, ISS, Champaign, IL), fluorescence intensity-fluctuation data was collected. A 
488 nm laser diode was used as an excitation source and was passed through a 514 nm 
long pass edge filter before detection. A Nikon Ti-U microscope (60x/1.2 NA water 
immersion objective lens) was used to direct excitation light to the experimental samples, 
while two Hamamatsu H7422P-40 photomultiplier tubes assessed the emission signal. 
The dimensions of the confocal volume were determined by using rhodamine 110 (R110) 
as a standard at known concentrations with a diffusion coefficient of D = 440 (µm2s-1). 
The results are reported as an average of 9 measurements in different positions within the 
sample to ensure solution homogeneity and sample times were 30 seconds in all cases. 
The FCS data was analyzed using Vista Vision Software (ISS Champagne, IL) to 
determine the diffusion coefficients. PEI was labeled with AlexaFlour 488 as described 
above and diluted to a final concentration of 100 µg/mL for the uncomplexed PEI 
samples. For BM, SMF, and MS samples the final concentration of DNA is the same as 
for transfections at 10 µg/mL and a PGA/PEI/DNA ratio of 1.2/1.8/1.0. 
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6.3 Results  
 
6.3.1 Device Design 
A previous device that was developed by our group, discussed in detail in Chapter 
4, for the production of PEI/DNA polyplexes incorporating a unique separation 
mechanism for the removal of free PEI was employed as a first step in the production of 
ternary polyplexes. A problem commonly encountered in the assembly of ternary 
polyplexes is the formation of “ghost” particles, complexes of free PEI remaining the 
binary polyplex suspension and the polyanion, which contain no DNA [133]. Assembly 
of PEI/DNA polyplexes in a MS device, which removes free PEI, is expected to yield 
fewer ghost particles when the binary polyplexes are mixed with a polyanion. In addition, 
we compared TPs assembled in this fashion with TPs produced in a SMF device, which 
introduces PEI and DNA to form binary polyplexes similar to previously reported devices 
and subsequently introduces PGA on the same microfluidic device after the PEI and 
DNA polyplexes have come into contact [16,17] [Fig. A.3]. In this case the channel 
lengths in which diffusion can occur are much shorter than that of the MS device and 
comparable to previously reported devices. Fluorescence microscopy of the SMF device 
shows that two distinct diffusion interfaces are formed by the device [Fig: A.4].  
 
6.3.2 Physicochemical Properties of Ternary Polyplexes 
Particle size and zeta potential of polyplexes formed by each of the formulation 
methods at a PEI/DNA ratio of 1.2:1 (w:w) and over PGA/DNA ratios from 0.6:1 to 3.0:1 
(w:w) are shown in Figure 6.1. Particle sizes measured upon formation of the  
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Figure 6.1: Comparison of physicochemical properties of TPs produced by different 
methods. average particle sizes (A), size polydispersity (B), and zeta-potential (C) of 
PGA/PEI/DNA polyplexes produced either by BM , SMF, or MS techniques over a range 
of W:W’s. Error bars represent the mean  ± S.E.M. (n=3). *P<0.05 and **P<0.01 for MS 
compared to BM polyplexes.  
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PGA/PEI/DNA polyplexes by the MS device were not significantly different from 
polyplexes produced by bulk mixing, ranging from 650 – 1800 nm. Particle sizes 
observed when PGA/PEI/DNA polyplexes were produced by the SMF device were 
smaller than those produced by either of the other mixing methods, ranging from 10 – 
100 nm. The similarity in particle sizes between BM and MS polyplexes may be 
attributed to the subsequent bulk mixing of the MS polyplexes to create ternary 
polyplexes, since the polyanionic coating is added in a non-controlled manner. The 
smaller particle sizes observed with the SMF produced polyplexes is likely due to the 
presence of a significant amount of ghost particles produced by the interaction of PEI and 
PGA before the PEI can diffuse into the DNA-containing stream. 
Zeta potentials of PGA/PEI/DNA TPs produced by BM ranged from -8 mV – -50 
mV, becoming increasingly negative as the amount of PGA in the complexes increased 
(Figure 6.1C). The minimum zeta potential was -42 mV at PGA/DNA ratio 3:1 (w:w) as 
would be expected. Similarly, the zeta potential of the MS-produced polyplexes grew 
increasingly negative with increasing amounts of PGA. However, the minimum value in 
this case plateaued at approximately -30 mV at PGA/DNA ratio 1.2:1 (w:w). For TPs 
fabricated in the SMF device, the zeta potentials ranged from +15 to -30 mV, and 
negatively charged particles were not observed until PGA/DNA ratio of 2.4 (w:w).  
 
6.3.3 Transfection with PGA/PEI/DNA Ternary Polyplexes 
TPs produced by all three formulation methods were used to transfect HeLa, 
MDA-MB-231 and U-87 MG cell lines, in both the absence and presence of serum. The 
PGA/PEI/DNA ternary polyplexes were assembled at a fixed PEI/DNA ratio of 2:1 
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(w:w), while the PGA/DNA ratio was varied from 0:1 to 3:1 (w:w). In the absence of 
serum, the MS-produced polyplexes, at all PGA/DNA ratios, mediated significantly 
increased transgene expression compared to either of the other two methods in HeLa and 
MDA-MB-231 cells. Maximum differences in transgene expression mediated by TPs 
fabricated by the MS device, compared to BM and the SMF device, were observed at 
PGA/PEI/DNA ratio of 0.6:2:1 and 1.2:2:1 (w:w:w) in HeLa and MDA-MB-231 cells, 
respectively. MS-produced TPs exhibited 2.2- and 23-fold increases in transgene 
expression in comparison to BM TPs in HeLa and MDA-MB-231 cells, respectively at 
the optimum ratios. SMF-produced polyplexes showed significantly decreased transgene 
expression compared to TPs produced by either of the other two methods at all ratios for 
the HeLa and MDA-MB-231 cell lines. Significant drops in gene expression for the 
SMF-produced TPs was also noted for the case of U87-MG cells at PGA:DNA ratios 
above 0.6.  
Similar results to the serum-free transfections were observed with those carried 
out in serum containing media, with the notable difference being the large increase in 
transfection activity for the TPs in comparison to PEI/DNA polyplexes. MS-produced 
polyplexes showed significantly greater transgene expression compared to both BM- and 
SMF-produced polyplexes in both HeLa and MDA-MB-231 cells, while no increases in 
transgene expression were observed in the U-87 MG cell line. In the case of transfections 
carried out in media containing serum, the highest gains in gene expression, when 
comparing BM to MS produced polyplexes, were observed at w/w’s of 1.8 for both cell 
lines with a 3.3- and 12-fold increase for HeLa and MDA-MB-231 cell lines respectively.  
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Figure 6.2: Serum-free transfections of three cell lines with TPs produced by different 
methods. Transfection of (A) HeLa, (B) MDA-MB-231, and (C) U-87 MG cells by 
PGA/PEI/DNA polyplexes assembled by BM, SMF, and MS techniques in serum-free 
media. Transfection efficiency is expressed as luciferase activity mediated by polyplex 
transfection normalized to luciferase activity mediated by transfection mediated by 
Lipofectamine 2000 carried out at the same time. Error bars represent the mean  ± S.E.M 
(n=3). *P<0.05 and **P<0.01 for MS compared to BM polyplexes at the same 
PGA/DNA ratio. 
 
 
 
 
 
Figure 6.3: In serum transfections of three cell lines with TPs produced by different 
methods. Transfection of (A) HeLa, (B) MDA-MB-231, and (C) U-87 MG cells by 
PGA/PEI/DNA polyplexes assembled by BM, SMF, and MS techniques in media 
containing 10% FBS. Transfection efficiency is expressed as luciferase activity mediated 
by polyplex transfection normalized to luciferase activity mediated by transfection 
mediated by Lipofectamine 2000 carried out at the same time. Error bars represent the 
mean  ± S.E.M (n=3). *P<0.05 and **P<0.01 for MS compared to BM polyplexes at the 
same PGA/DNA ratio.  
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6.3.4 Cellular Internalization of Ternary Polyplexes 
To assess the relative amounts of TPs internalized by the cells, transfections were 
carried out in HeLa, MDA-MB-231 and U-87 MG cell lines with TPs containing 
fluorescently labeled DNA at their optimal PGA/PEI/DNA ratios, and fluorescence 
resulting from internalized TPs was quantified by flow cytometry. In this case only the 
optimum w/w’s for gene expression were tested and the transfections were carried out in 
serum-free media. Interestingly, SMF-produced TPs exhibited the highest cellular uptake 
in the HeLa and U-87 MG cell lines, while in both cases these same polyplexes showed 
significantly reduced transfection efficiency in comparison to TPs fabricated using the 
other two methods. MS-produced TPs demonstrated significant increases in uptake in 
comparison to BM-produced polyplexes in both HeLa and MDA-MB-231 cell lines and 
no significant increase in the U-87 MG cell line.  Uptake was 20% and 10% higher for 
the MS-produced TPs in comparison to the BM produced TPs in these two cell lines. 
 
6.3.5 Cytotoxicity of Ternary Polyplexes 
Cytotoxicity was as assessed by measuring cellular metabolic activity in all three 
cell lines after transfection with TPs produced by the three different methods at a 
PGA/PEI/DNA ratio of 1.2:2:1 (w:w:w) in media containing serum and serum-free 
media. In the absence of serum, MS-produced TPs demonstrated greater cell viability 
than both BM- and SMF-produced polyplexes in the HeLa and U87-MG cell lines.   
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Figure 6.4: Cellular uptake analysis of TPs produced by different methods on HeLa cells. 
Flow cytometry data to probe cellular uptake of the TPs at PGA/PEI/DNA ratio of 
1.2/1.8/1 for HeLa, MDA-MB-231 and U87-MG cell lines. Error bars represent the mean  
± S.E.M (n=3). *P<0.05 and **P<0.01 for MS compared to BM polyplexes 
.  
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Figure 6.5: Cell viability as assessed by cell titer blue assay on HeLa, MDA-MB-231, 
and U87-MG cells both in serum-free (A) and Serum containing (B) media. Data 
expressed as percent of untreated control. Error bars represent the mean  ± S.E.M (n=3). 
*P<0.05 and **P<0.01 for MS compared to BM polyplexes.  
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6.3.6 Determination of Free Polymer and Ghost Particles in Ternary Polyplex 
Suspensions 
By measuring the fluorescence fluctuations emitted from labeled molecules 
moving in and out of the confocal volume, fluorescence correlation spectroscopy (FCS) 
allows for the determination of the diffusion coefficient of particle within a sample. The 
confocal detection optics, excitation volume of the focused laser beam, and 
characterizing the measurements against a standard of known diffusion constant (R110) 
gives a fixed effective illumination volume. The measured fluctuations are then compared 
after a lag time τ for similarity by calculating the normalized cross correlation G(τ): 
                                               𝐺 τ = 1 + -.(0)-.(023)
.(0) 4
                                                   (1) 
Here δF(t) is the deviation from the mean fluorescence, F(t), at a given time and δF(t+ τ) 
is the deviation from the mean fluorescence at the same time plus a lag time τ. A general 
time autocorrelation function for fluorescent particles that are uniformly distributed, and 
undergoing ideal Brownian motion, can be used to model the fluorescence fluctuations 
and give data about the sample, such as the diffusion coefficient. The general 
autocorrelation function is: 
                                          𝐺 τ = 1 + 5
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                                     (2) 
Here ω and z are constants specific to the instrument, τ is the lag time, and xi is the 
fraction of particles with the translational diffusion time τD,i. Therefore the diffusion 
coefficient, D, of the particles can be determined by the following equation: 
                                                           τC,< =
D4
EC:
                                                                (3) 
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Figure 6.6: Determination of free polymer and ghost particles by FCS. Normalized 
autocorrelation curves for free PEI, BM, SMF, and MS methods. PGA/PEI/DNA weight 
ratios are all at 1.2/1.8/1.0 where applicable. Error bars represent the mean  ± S.E.M 
(n=9).  
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For this set of experiments a two-component fit was employed to distinguish 
between TPs and free PEI or a combination of free PEI and ghost particles. FCS data 
show a distinct shift for MS-produced polyplexes to the right in comparison to free PEI, 
BM-produced TPs, or SMF-produced TPs [Fig. 6]. The BM-produced TP and free PEI 
samples yield autocorrelation curves that are very similar with the SMF-produced TP 
sample, having a curve that is slightly shifted in comparison to the BM sample curve.   
The fractions of free PEI determined by the autocorrelation function were determined to 
be 97.5, 80.0, and 0.0 for the BM-, SMF-, and MS-produced TPs, respectively. 
6.4 Discussion  
Polymeric gene delivery vectors offer the potential to circumvent many of the 
drawbacks associated with viral gene delivery vectors. Ternary polyplexes allow for 
enhancement of conventional two-component polyplexes by improving transfections in 
the presence of serum, reducing cytotoxicity, and potentially allowing for more flexibility 
in overcoming cellular barriers to delivery. Microfluidics can allow for the further 
advancement of polyplex formulations by allowing for the continuous production of 
polyplexes and the removal of excess components that are known to be toxic to cells.  
 Two microfluidic devices for assembly of TPs were designed and constructed, 
and the resulting vectors were compared to BM-produced TPs for their physicochemical 
characteristics and gene delivery activity. First, a novel sequential mixing device was 
created based on previous research that allows for the introduction of DNA and PEI to 
form a stream rich in PEI/DNA polyplexes, which is then hydrodynamically focused by a 
PGA stream. It was initially thought that the larger diffusivity of both PEI and PGA 
relative to DNA would lead to rapid mixing of PEI and PGA, which would then lead to 
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the formation of ghost particles possessing no transfection activity. A previous device, 
designed by our group, containing a separation mechanism, was also employed to first 
make PEI/DNA polyplexes that have been shown to have reduced amounts of free PEI 
and enhanced transfection activity, and then bulk mixed with PGA to produce TPs 
containing fewer ghost particles and thus enhanced transfection activity. 
 Physicochemical properties of TPs produced by the various mixing methods were 
first explored by DLS. It was shown that particle sizes of the MS-produced polyplexes 
were not significantly different than those of TPs produced by BM. The similarity in 
particle sizes in this case is most likely due to the bulk mixing of PGA, which occurs 
after the MS production of PEI/DNA polyplexes. SMF-produced TPs were the smallest at 
all PGA/DNA ratios. This may be due to the presence of a higher concentration of ghost 
particles, which are expected to be smaller than polyplexes [133]. This suggests that 
microfluidic production of the TPs on a single device would be ideal, but would require 
separation mechanisms within the chip, which will be the subject of future research.  
 Transfections mediated by TPs produced by the three different methods revealed 
that the removal of free PEI from the polyplex suspensions using the MS device led to 
enhanced transgene expression in the HeLa and MDA-MB-231 cell lines. The increases 
in transfection activity were observed both in serum-free media and media containing 
serum. Additionally, the MS-produced TPs perform about the same as BM TPs in the U-
87 MG cell line, showing that, even in cell lines where separation may not provide gene 
expression enhancement, MS still may lead to a method for the continuous microfluidic 
production of TPs, which holds particular relevance for the processing and manufacturing 
of such drugs.  
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Quantitation of cellular internalization revealed that MS-produced TPs are taken 
up by a significantly greater percentage of HeLa cells than BM TPs, which may explain 
the increased gene expression seen in this cell line. HeLa cells show a significantly 
reduced cellular uptake than the other two cell lines, while simultaneously exhibiting the 
highest gene delivery activity. This may be due to a combination of cell surface receptors 
expressed by the cell line and generally lower metabolic activity associated with this 
specific cell line. It is interesting to note that while transgene expression was higher in 
most cases with the MS-produced polyplexes, cellular uptake was highest for the SMF-
produced polyplexes in many instances. This may be due to membrane disruption 
associated with free PEI or ghost particles, allowing for more accessible entry into cells 
for the tagged DNA. The exact source of the combination of increased cellular uptake 
and reduced gene expression is unknown and needs to be further explored. 
FCS data demonstrates further the ability of the MS device to separate free PEI 
from the polyplex sample. The two-component fit of the autocorrelation shows slower 
diffusion times for the sample and essentially no free PEI left in the resulting MS-
produced polyplexes. In the case of the SMF device, the FCS data provides further 
evidence of the presence of a large amount of ghost particles when taking transfection 
data and particle size data into account as well. Since the FCS data indicate the sample 
has a similar amount of free PEI, while the transfection activity was very low and particle 
sizes were very small, these data seem to imply the presence of ghost particles.    
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6.6 Conclusions 
Here we have described a method for the production of TPs using microfluidics 
and show that TPs produced by this method have higher transfection activity than those 
produced by BM in HeLa and MDA-MB-231 cell lines. Additionally, MS-produced 
polyplexes contained few ghost particles when compared to SMF-produced polyplexes, 
and also higher transfection activity in all cell lines explored. Lower cytotoxicity was also 
noted at optimal PGA/PEI/DNA ratios for the MS-produced polyplexes in comparison to 
BM-produced polyplexes. 
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Chapter 7: Conclusions and Future Perspectives 
	
In this work, I explored the development of microfluidic devices for the 
production of non-viral polymeric-based gene delivery vectors. This dissertation 
demonstrated several key findings for this method of polyplex production. First in 
Chapter 4, it was shown that since polyethylenimine (PEI) and DNA diffuse at vastly 
different rates, it was feasible to separate free PEI from a product stream of a 
hydrodynamic focusing (HF) microfluidic device. Polyplexes produced by the 
microfluidic separator (MS) device were shown to be significantly smaller at some 
compositions. Transfections carried out over a range of PEI/DNA ratios showed that for 
some cell lines and at some compositions, MS-produced polyplexes demonstrated 
increased transfection efficiencies and decreased cellular toxicities. Importantly, through 
agarose gel electrophoresis, it was shown that MS-produced polyplexes yielded a product 
that contained ~40% less free PEI than BM-produced polyplexes. We then optimized 
mixing methods and PGA molecular weight for the production of ternary polyplexes in 
Chapter 5. It was shown that previous BM methods employed for the production of 
polyplexes may not have been ideal in the order in which polyplexes were mixed, and 
that for the production of ternary polyglutamic acid (PGA)/PEI/DNA polyplexes it was 
essential to first mix PEI with DNA and subsequently introduce PGA. This result paved 
the way for moving forward with the microfluidic production of ternary polyplexes 
discussed in Chapter 6. Additionally, in Chapter 5, it was shown that for the production 
of PGA/PEI/DNA polyplexes, 15-kDa PGA showed the most versatility for transfecting 
cells both in serum-free media and media containing serum. Chapter 6 explored strategies 
for the microfluidic production of ternary polyplexes. The design of a SMF device and 
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comparison of the polyplexes produced to both BM polyplexes and those produced by the 
MS device showed that separation of free PEI was beneficial for optimum transfection 
efficiencies and reduction of cytotoxicity in multiple cell lines in both serum-free and 
serum-containing media. Cellular uptake was shown to be enhanced by the separation of 
free PEI through flow cytometry studies carried out in multiple cell lines at the optimum 
transfection compositions. 
 Uniquely, we have demonstrated the development and utility of a microfluidic 
separation system for the production of both binary and ternary polymeric gene delivery 
vectors. Continuous production of pharmaceuticals can be difficult to accomplish due to 
the complex purification processes that are often necessary. In this case we have 
demonstrated a cheap and reliable method for the removal of toxic free PEI from the final 
drug product and simultaneous enhancements to the quality of the product. Although 
production volumes used throughout this research project have remained much smaller 
than those required for commercial production, this technique is easily scalable through 
the use of multiple parallel microfluidic systems.  
 
7.1 Future Perspectives 
 The results presented in this dissertation suggest that MS is a promising advance 
for the continuous production of enhanced ternary polyplexes of high quality. However 
there are still steps to be taken to further advance this technique towards implementation 
on a commercial scale. The sections that follow give details about these challenges and 
the future goals of this research. 
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7.1.1 A Nested Device for the Production of Ternary Polyplexes 
 This work has demonstrated the utility of a microfluidic separation device for the 
production of purified binary polyplexes that can then be mixed with PGA to produce 
high-quality ternary polyplexes. However, one of the key end points for quality 
enhancement for this type of therapeutic is a controllable and consistent particle size. It 
was shown that in cases when all steps of polyplex production occurred within a 
microfluidic device, particle sizes were consistent and predictable. Moving forward we 
will continue this work by integrating the developed separation system into a nested 
microfluidic system that is capable of fabricating binary polyplexes, separating free PEI, 
and then introducing PGA, thus fabricating layer-by-layer ternary polyplexes all on one 
device [Fig 7.1]. A key point of emphasis for achieving this goal will be demonstrating 
the ability to control pressures at the various outlets to achieve the desired flow 
characteristics. We hypothesize that if the flow is manipulated by pressure controllers the 
desired flow rates will be achievable and, importantly, ternary polyplexes with 
predictable and consistent sizes can be produced. We believe that this will lead to 
polyplexes with enhanced properties such as lower cytotoxicity and increased 
transfection efficiency. Also, since this would be a more continuous approach to the 
production of ternary polyplexes, it would yield a more economically viable method for 
the production of the therapeutic. Taken together, these results would be a significant step 
towards clinically and commercially viable non-viral gene delivery vectors.  
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Figure 7.1: Nested microfluidic device design concept for the production of high quality 
ternary polyplexes.  
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7.1.2 Integrating More Complex Ternary Polyplex Systems 
 After the development of an all-in-one device for the production of ternary 
polyplexes, we believe the device could easily be adapted for the production of ternary 
polyplexes that include more advanced polymers such as the ones mentioned previously 
in the manuscript. Targeting polymers could easily be adapted to the system and 
implemented in second hydrodynamic focusing section on the device yielding TPs of 
consistent quality coated with targeting polymers. For example, FPP/PEI/DNA 
polyplexes might be well-suited for such a system yielding TPs that target folate 
receptors, which are over-expressed by many cancerous cells. The nested device 
mentioned above could lead to enhanced quality of TP systems such as this one. 
Additionally, it is clear that there are many such TP systems throughout this dissertation 
that address many of the cellular barriers to delivery that might be well-suited to such a 
system and be aided by the aforementioned benefits. 
 Addressing other challenges for clinical implementation of non-viral gene 
delivery vectors may also be possible by allowing for the continuous production of the 
TPs and freeze-dried storage. These very plausible improvements address two significant 
technical boundaries aiding in commercial success of non-viral vectors. Approaching the 
transfection efficiency of viral vectors, and thus competing with them as a viable 
alternative, is a significant challenge. However, we believe through implementation of 
microfluidic production and intelligent vector design, the ability of non-viral gene 
delivery vectors to address cellular barriers to delivery will be significantly enhanced. 
The high transfection efficiency of viral vectors is due to their highly evolved 
mechanisms to address cellular barriers to delivery. Thus, it is possible for the 
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transfection efficiency of polymeric-based vectors to approach that of viral vectors 
through these improvements. It is the opinion of the author that this research represents a 
significant advance towards commercially and clinically viable polymer-based gene 
delivery vectors. 
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Appendix 
 
 
Figure A.1: PEI outlet concentrations for the MS device at different PEI inlet 
concentrations as assessed by ninhydrin assay. 
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Figure A.2: Schematics for two different microfluidic devices with different diffusion 
lengths. A) 2 cm device, MF2. B) 25 cm device with 25 cm serpentine diffusion length, 
25M 
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Figure A.3: Schematic of SMF device. 
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Figure A.4: Fluorescence microscopy image of the second HF region of the SMF device.  
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